Π‘ΡΠ°ΡΠΈΠΈ ΠΎΡ Π΄ΡΡΠ³ΠΈ ΡΠΏΠΈΡΠ°Π½ΠΈΡ / Other Journal Articles
ΠΠΎΡΡΠΎΡΠ½Π΅Π½ URI Π·Π° ΡΠ°Π·ΠΈ ΠΎΠ±ΡΠ½ΠΎΡΡ
ΠΠΎΠ»Π΅ΠΊΡΠΈΡΡΠ° ΡΡΠ΄ΡΡΠΆΠ° ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΈ ΠΎΡ ΡΠΏΠΈΡΠ°Π½ΠΈΡ (ΠΎΠ±Π·ΠΎΡΠΈ, ΠΎΠΏΠΈΡΠ°Π½ΠΈΠ΅ Π½Π° ΡΠ»ΡΡΠ°ΠΈ, ΠΎΡΠΈΠ³ΠΈΠ½Π°Π»Π½ΠΈ ΡΡΠ°ΡΠΈΠΈ):
β’pre-print Π΅ Π²Π΅ΡΡΠΈΡ Π½Π° ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π», ΠΊΠΎΠΉΡΠΎ Π½Π΅ Π΅ ΡΠ΅ΡΠ΅Π½Π·ΠΈΡΠ°Π½ ΠΈΠ»ΠΈ ΡΠΈΠ½Π°Π»Π½Π°ΡΠ° Π²Π΅ΡΡΠΈΡ Π½Π° Π°Π²ΡΠΎΡΠ°(Π°Π²ΡΠΎΡΠΈΡΠ΅).
β’post-print Π΅ Π²Π΅ΡΡΠΈΡ, ΠΏΡΠ΅ΠΌΠΈΠ½Π°Π»Π° ΠΏΡΠΎΡΠ΅ΡΠ° Π½Π° ΡΠ΅ΡΠ΅Π½Π·ΠΈΡΠ°Π½Π΅; ΡΠΈΠ½Π°Π»Π½Π°ΡΠ° Π²Π΅ΡΡΠΈΡ Π½Π° ΠΈΠ·Π΄Π°ΡΠ΅Π»Ρ.
ΠΡΠ΅Π³Π»Π΅ΠΆΠ΄Π°Π½Π΅
Π’ΡΡΡΠ΅Π½Π΅ Π‘ΡΠ°ΡΠΈΠΈ ΠΎΡ Π΄ΡΡΠ³ΠΈ ΡΠΏΠΈΡΠ°Π½ΠΈΡ / Other Journal Articles ΠΎΡ ΠΠ°Π³Π»Π°Π²ΠΈΠ΅
ΠΠΎΠΊΠ°Π·Π°Π½ΠΈ 1 - 20 ΠΎΡ 63
Π Π΅Π·ΡΠ»ΡΠ°ΡΠΈ Π½Π° Π²ΡΡΠΊΠ° ΡΡΡΠ°Π½ΠΈΡΠ°
ΠΠΏΡΠΈΠΈ Π·Π° ΡΠΎΡΡΠΈΡΠ°Π½Π΅
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡCimzia β Π½ΠΎΠ²Π° Π½Π°Π΄Π΅ΠΆΠ΄Π½Π° Π°Π»ΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π° Π·Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π° ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΠΈΡ Π°ΡΡΡΠΈΡ(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2011-12) Π¨Π΅ΠΉΡΠ°Π½ΠΎΠ²/Sheytanov, Π./I.; Π Π°ΡΠΊΠΎΠ²/Rashkov, Π ./R.; ΠΠ΅ΡΡΠ°Π½ΠΎΠ²Π°/Petranova, Π¦Π²./Tsv.Π Π΅Π·ΡΠΌΠ΅. Π Π΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΠΈΡΡ Π°ΡΡΡΠΈΡ (Π Π) Π΅ Ρ ΡΠΎΠ½ΠΈΡΠ½ΠΎ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎ Π²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΎ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅. ΠΠ½Π°ΡΠΈ- ΡΠ΅Π»Π½Π°ΡΠ° ΡΠ΅ΡΡΠΎΡΠ° Π½Π° Π Π, Π³ΠΎΠ»ΡΠΌΠ°ΡΠ° ΠΌΡ ΠΏΡΠΎΠ΄ΡΠ»ΠΆΠΈΡΠ΅Π»Π½ΠΎΡΡ ΠΈ ΡΠ΅ΠΆΠΊΠΈΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ, ΠΊΠΎΠΈΡΠΎ ΠΏΡΠ΅Π΄ΠΈΠ·- Π²ΠΈΠΊΠ²Π° Π²ΡΠ² ΡΡΠ½ΠΊΡΠΈΠΈΡΠ΅ Π½Π° ΠΎΠΏΠΎΡΠ½ΠΎ-Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»Π½ΠΈΡ Π°ΠΏΠ°ΡΠ°Ρ Ρ ΠΏΡΠΎΠΈΠ·ΡΠΈΡΠ°ΡΠΈΡΠ΅ ΠΎΡ ΡΠΎΠ²Π° ΠΏΠΎΡΠ»Π΅Π΄ΠΈΡΠΈ, ΠΎΠΏΡΠ΅- Π΄Π΅Π»ΡΡ Π½Π΅Π³ΠΎΠ²Π°ΡΠ° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° ΠΈ ΡΠΎΡΠΈΠ°Π»Π½Π° Π·Π½Π°ΡΠΈΠΌΠΎΡΡ. ΠΡΠ½ΠΎΠ²Π½Π°ΡΠ° ΡΠ΅Π» Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ ΠΏΡΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄- Π½ΠΈΡ Π°ΡΡΡΠΈΡ Π΅ ΠΏΠΎΡΡΠΈΠ³Π°Π½Π΅ΡΠΎ Π½Π° Π½ΠΈΡΠΊΠ° Π±ΠΎΠ»Π΅ΡΡΠ½Π° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡ, Π° Π² ΠΈΠ΄Π΅Π°Π»Π½ΠΈΡ ΡΠ»ΡΡΠ°ΠΉο οο ΠΈ Π½Π° ΠΏΡΠ»Π½Π° ΡΠ΅ΠΌΠΈ- ΡΠΈΡ. ΠΡΠ΅Π· ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡΠ΅ Π³ΠΎΠ΄ΠΈΠ½ΠΈ Π΅ Π½Π°Π»ΠΈΡΠ΅ Π·Π½Π°ΡΠΈΡΠ΅Π»Π΅Π½ ΠΏΡΠΎΠ³ΡΠ΅Ρ Π² Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ Π½Π° ΡΠ°Π·ΠΈ Π±ΠΎΠ»Π΅ΡΡ Ρ ΠΎΡΠΊΡΠΈ- Π²Π°Π½Π΅ ΠΈ Π½Π°Π»Π°Π³Π°Π½Π΅ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ½Π°ΡΠ° ΠΏΡΠ°ΠΊΡΠΈΠΊΠ° Π½Π° TNF-Ξ± ΠΈΠ½Ρ ΠΈΠ±ΠΈΡΠΎΡΠΈΡΠ΅. ΠΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½eΡΠΎ Π½Π° ΡΠ΅Π·ΠΈ ΠΌΠ΅Π΄ΠΈΠΊΠ°- ΠΌΠ΅Π½ΡΠΈ Ρ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°Ρ (ΠΠ’Π₯) Π΄Π°Π²Π° Π½Π°ΠΉ-Π΄ΠΎΠ±ΡΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½ΠΈ ΡΠ΅Π·ΡΠ»ΡΠ°ΡΠΈο οο ΠΏΡΠΈ Π·Π°Π΄ΠΎΠ²ΠΎΠ»ΠΈΡΠ΅Π»Π΅Π½ ΠΏΡΠΎ- ΡΠΈΠ» Π½Π° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ. ΠΠ½ΠΈΠΌΠ°Π½ΠΈΠ΅ΡΠΎ Π² ΠΎΠ±Π·ΠΎΡΠ° Π΅ Π½Π°ΡΠΎΡΠ΅Π½ΠΎ ΠΊΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Cimzia (Certolizumab pegol). ΠΡΠ΅Π΄ΡΡΠ°Π²Π΅Π½ΠΈ ΡΠ° Π΄Π²Π΅ Π³ΠΎΠ»Π΅ΠΌΠΈ ΠΌΠ½ΠΎΠ³ΠΎΡΠ΅Π½ΡΡΠΎΠ²ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ½ΠΈ ΠΏΡΠΎΡΡΠ²Π°Π½ΠΈΡ, ΠΎΡΠ΅Π½ΡΠ²Π°ΡΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½Π°ΡΠ° Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π° Π½Π° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ Π½Π° Π‘ertolizumab pegol ΠΏΡΠΈ Π±ΠΎΠ»Π½ΠΈ Ρ Π°ΠΊΡΠΈΠ²Π΅Π½ Π Π. ΠΠ°ΠΏΡΠ°Π²Π΅Π½ΠΎ Π΅ Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΡΠΎ, ΡΠ΅ Cimzia Π΅ Π΅Π΄Π½Π° Π½Π°Π΄Π΅ΠΆΠ΄Π½Π° ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½Π° Π°Π»ΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π° Π½Π° ΠΎΡΡΠ°Π½Π°Π»ΠΈΡΠ΅ TNF-Ξ± Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΈ ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ Π½Π° ΡΠ°Π·ΠΈ ΡΠ΅ΠΆΠΊΠ° Ρ ΡΠΎΠ½ΠΈΡΠ½Π° Π±ΠΎΠ»Π΅ΡΡ. ***** of RA, its long duration and serious damages, that are caused in the functions of the musculoskeletal system with resulting consequences, determine its medical and social significance. The main goal of rheumatoid arthritis treatment is to achieve low disease activity and, ideally, complete remission. In recent years, significant progress has been made in the treatment of this disease through the development and implentation of TNF-Ξ± inhibitors in clinical practice. The combination of these medicines with methotrexate (MTX) gives the best therapeutic results with a good safety profile. The focus of this review is aimed at Cimzia (certolizumab pegol). The presented two large multicenter clinical trials evaluate the therapeutic efficacy and safety profile of certolizumab pegol in patients with active RA. It is concluded that Cimzia is a reliable therapeutic alternative to other TNF-Ξ± antagonists in the treatment of this severe chronic disease.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡEffectiveness of the application of a digitalized repository on the quality of graduate and post-graduate education in the field of physical medicine and rehabilitation(Frontiers Media SA, 2025-01-07) Koleva, Ivet B.; Yoshinov, Borislav R.; Yoshinov, Radoslav R.Background: During last ten years, we have developed a digital library with educational materials in Physical medicine and rehabilitation. Objectives: The objective of current article is the preparation of an electronic library with educational materials in the area of physical medicine, physical therapy and rehabilitation, and the comparative evaluation of the impact of this repository on the quality of education of students and trainees in the field. Methodology: The electronic library includes e-books on different topics, elements of the specialty βPhysical and rehabilitation medicine (PRM)β or Physiatry β with theoretical data, practical issues and case reports with videos of real patients. From the field of basic physiatry we included: books on kinesiological and pathokinesiological analysis, functional evaluation; physiotherapy (active exercises, soft-tissue techniques), ergotherapy (activities), balneotherapy (mineral baths and peloids, underwater gymnastics), manual therapy (tractions, mobilizations, manipulations), preformed physical factors (electric currents, magnetic field, ultrasound, light, laser, etc). In special physiatry we prepared manuals on: neurological and neurosurgical rehabilitation, orthopedic and traumatologic rehabilitation, rheumatologic rehabilitation, cardiac and cardiosurgical rehabilitation, etc. The digital library has been applied to educate 1,186 learners (graduate and post-graduate studies): students in Bachelorβs degree (Physiotherapy, Nursing, Midwifery, Medical assistants) and in Masterβs degree (Physiotherapy, Medical rehabilitation and balneology), medical doctorsβresidents in Physical and Rehabilitation medicine (PRM), participants in long-life learning courses (physiatrists, physiotherapists and nurses). At the end of every educational course, we collected data from the practical and theoretical exams (investigation periodβfrom April 2020 to October 2024). Additionally, we evaluated learnersβ opinion using anonymous questionnaires on the usefulness of the electronic library. Results: Comparative analysis of the results revealed significant improvement in theoretical knowledge and practical skills of students and trainees, as evidenced by online assessments, and face-to-face theoretical and practical exams. The majority of learners consider the electronic repository useful. Conclusion and recommendations: The authors consider this electronic library (with books, manuals, video-presentations and case studies) a valuable resource in both graduate and post-graduate education within the rehabilitation field. We recommend the application of electronic repositories in the process of education of the students and trainees.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡEthical Legal and Professional Prerequisites and directions for the autonomous regulation of the dental profession // ΠΠΎΡΠ°Π»Π½ΠΈ, ΠΏΡΠ°Π²Π½ΠΈ ΠΈ ΠΏΡΠΎΡΠ΅ΡΠΈΠΎΠ½Π°Π»Π½ΠΈ ΠΏΡΠ΅Π΄ΠΏΠΎΡΡΠ°Π²ΠΊΠΈ ΠΈ Π½Π°ΡΠΎΠΊΠΈ Π·Π° Π°Π²ΡΠΎΠ½ΠΎΠΌΠ½ΠΎΡΠΎ ΡΠ΅Π³ΡΠ»ΠΈΡΠ°Π½Π΅ Π½Π° ΡΡΠΎΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½Π°ΡΠ° ΠΏΡΠΎΡΠ΅ΡΠΈΡ(ΠΠ¦ΠΠ Π‘ΠΎΡΠΈΡ, 1999) ΠΠ°ΡΡΠΎΠ²Π°, ΠΠΈΠ΄ΠΈΡ // Katrova, LydiaAbstract. Autonomy as a core feature of dentistry was reestablished along the reestablishment of democracy and market economy in Bulgaria. This process comprises moral, legal and professional aspects. The purpose of this study is to analyze interdependence between professionalism and ethics and to define a model of ethical system of the dental practitioner. The need for consensus on formulating the rules of professionalism in dentistry taking into consideration the complex valuesβ and institutionsβ impacts was reviewed. Integration of ethical education in the dental curriculum and continuing education in dentistry is suggested. // Π Π΅Π·ΡΠΌΠ΅. ΠΠ²ΡΠΎΠ½ΠΎΠΌΠΈΡΡΠ°, ΠΊΠ°ΡΠΎ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π° ΡΠ΅ΡΡΠ° Π½Π° Π·ΡΠ±ΠΎΠ»Π΅ΠΊΠ°ΡΡΠΊΠ°ΡΠ° ΠΏΡΠΎΡΠ΅ΡΠΈΡ, Π±Π΅ΡΠ΅ Π²ΡΠ·ΡΡΠ°Π½ΠΎΠ²Π΅Π½Π° ΡΡΠΏΠΎΡΠ΅Π΄Π½ΠΎ Ρ Π²ΡΠ·ΡΡΠ°Π½ΠΎΠ²ΡΠ²Π°Π½Π΅ΡΠΎ Π½Π° Π΄Π΅ΠΌΠΎΠΊΡΠ°ΡΠΈΡΡΠ° ΠΈ ΠΏΠ°Π·Π°ΡΠ½Π°ΡΠ° ΠΈΠΊΠΎΠ½ΠΎΠΌΠΈΠΊΠ° Π² ΠΡΠ»Π³Π°ΡΠΈΡ. ΠΡΠΎΡΠ΅ΡΡΡ ΡΠ΅ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΈΡΠ° Ρ ΠΌΠΎΡΠ°Π»Π½ΠΈ, Π·Π°ΠΊΠΎΠ½ΠΎΠ²ΠΈ ΠΈ ΠΏΡΠΎΡΠ΅ΡΠΈΠΎΠ½Π°Π»Π½ΠΈ Π°ΡΠΏΠ΅ΠΊΡΠΈ. Π¦Π΅Π»ΡΠ° Π½Π° ΠΈΠ·ΡΠ»Π΅Π΄Π²Π°Π½Π΅ΡΠΎ Π΅ Π΄Π° Π°Π½Π°Π»ΠΈΠ·ΠΈΡΠ° Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡΠ° ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΡΠΎΡΠ΅ΡΠΈΠΎΠ½Π°Π»ΠΈΠ·ΡΠΌ ΠΈ Π΅ΡΠΈΠΊΠ° ΠΈ Π΄Π° Π΄Π΅ΡΠΈΠ½ΠΈΡΠ° ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΈΡΠ΅ Π½Π° ΠΌΠΎΠ΄Π΅Π» Π½Π° Π΅ΡΠΈΡΠ½Π° ΡΠΈΡΡΠ΅ΠΌΠ° Π·Π° ΠΏΡΠ°ΠΊΡΠΈΠΊΡΠ²Π°ΡΠΈΡΠ΅ Π·ΡΠ±ΠΎΠ»Π΅ΠΊΠ°ΡΠΈ. ΠΠ°ΠΏΡΠ°Π²Π΅Π½ Π΅ ΠΏΡΠ΅Π³Π»Π΅Π΄ Π½Π° Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎΡΡΡΠ° ΠΎΡ Π΅Π΄ΠΈΠ½Π½ΠΎ ΡΠΎΡΠΌΡΠ»ΠΈΡΠ°Π½Π΅ Π½Π° ΠΏΡΠ°Π²ΠΈΠ»Π° Π½Π° ΠΏΡΠΎΡΠ΅ΡΠΈΠΎΠ½Π°Π»ΠΈΠ·ΡΠΌ Π² Π·ΡΠ±ΠΎΠ»Π΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ ΠΊΠ°ΡΠΎ ΡΠ΅ Π²Π·Π΅ΠΌΠ°Ρ ΠΏΡΠ΅Π΄Π²ΠΈΠ΄ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΈΡΠ΅ ΡΠ΅Π½Π½ΠΎΡΡΠ½ΠΈ ΠΈ ΠΈΠ½ΡΡΠΈΡΡΡΠΈΠΎΠ½Π°Π»Π½ΠΈ Π²Π»ΠΈΡΠ½ΠΈΡ. ΠΠ±ΡΡΠΆΠ΄Π° ΡΠ΅ Π²ΠΊΠ»ΡΡΠ²Π°Π½Π΅ΡΠΎ Π½Π° ΠΏΡΠΎΡΠ΅ΡΠΈΠΎΠ½Π°Π»Π½Π°ΡΠ° Π΅ΡΠΈΠΊΠ° ΠΊΠ°ΠΊΡΠΎ Π² ΡΡΠ΅Π±Π½Π°ΡΠ° ΠΏΡΠΎΠ³ΡΠ°ΠΌΠ° Π·Π° ΡΡΡΠ΄Π΅Π½ΡΠΈΡΠ΅ ΡΠ°ΠΊΠ° ΠΈ Π² ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΈΡΠ΅ Π·Π° Π½Π΅ΠΏΡΠ΅ΠΊΡΡΠ½Π°ΡΠΎΡΠΎ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠ΅ Π½Π° ΠΏΡΠ°ΠΊΡΠΈΠΊΡΠ²Π°ΡΠΈΡΠ΅ Π»Π΅ΠΊΠ°ΡΠΈ ΠΏΠΎ Π΄Π΅Π½ΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π° Π² ΠΡΠ»Π³Π°ΡΠΈΡ.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡGolimumab (Simponi) ΠΏΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ Ρ Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΠ°Ρ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡ(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2011-12) ΠΠΎΠ½ΠΎΠ²/Monov, Π‘./S.; Π Π°ΡΠΊΠΎΠ²/Rashkov, Π ./R.Π½ΠΈΡΠ΅Ρ ΠΊΡΠΌ ΡΠΎΠ²Π΅ΡΠΊΠΈΡ TNF-Ξ±. ΠΡΠΎΡΡΠ²Π°Π½Π΅ΡΠΎ GO-RAISE ΠΈΠ·ΡΠ»Π΅Π΄Π²Π° Π΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΠ° ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡΠ° Π½Π° Golimumab ΠΏΡΠΈ 356 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ Ρ Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΠ°Ρ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡ (ΠΠ‘) Π½Π°Π΄ 18-Π³ΠΎΠ΄ΠΈΡΠ½Π° Π²ΡΠ·ΡΠ°ΡΡ Π·Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ ΠΎΡ 24 ΡΠ΅Π΄ΠΌΠΈΡΠΈ ΠΈ Ρ ΠΏΡΠΎΠ΄ΡΠ»ΠΆΠ΅Π½ΠΈΠ΅ Π΄ΠΎ Π΄Π²Π΅ Π³ΠΎΠ΄ΠΈΠ½ΠΈ. Π Π΅Π·ΡΠ»ΡΠ°ΡΠΈΡΠ΅ ΠΎΡ GO-RAISE Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠ°Ρ Π±ΡΡΠ· Π½Π°ΡΠ°Π»Π΅Π½ ΠΈ ΠΏΡΠΎΠ΄ΡΠ»ΠΆΠΈΡΠ΅Π»Π΅Π½ (104 ΡΠ΅Π΄ΠΌΠΈΡΠΈ) Π΅ΡΠ΅ΠΊΡ Π½Π° ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠ° ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠ²Π»ΠΈΡΠ²Π°Π½Π΅ Π°ΠΊΡΠΈΠ²- Π½ΠΎΡΡΡΠ° Π½Π° Π±ΠΎΠ»Π΅ΡΡΡΠ°, ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»Π½ΠΎΡΠΎ ΡΡΡΡΠΎΡΠ½ΠΈΠ΅ ΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎΡΠΎ Π½Π° ΠΆΠΈΠ²ΠΎΡ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅. Golimumab (Simponi) Π΅ Ρ Π΄ΠΎΠ±ΡΡ ΠΏΡΠΎΡΠΈΠ» Π½Π° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ ΠΏΡΠΈ ΠΠ‘. ***** Summary. Golimumab (Simponi) is a fully human monoclonal IgG1k antibody with pronounced affinity to human TNF-Ξ±. The GO-RAISE study examined the effectiveness and safety of Golimumab in 356 patients with ankylosing spondylitis (AS), aged over 18 years, for a period of 24 weeks and an extension of up to two years. The results of the GO-RAISE have demonstrated rapid initial and prolonged (104 weeks) effects of the drug in regard to disease activity, functional status and quality of life of patients. Golimumab (Simpomi) has a good safety profile in AS.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡIL-17 ΠΈ Π½Π΅ΡΡΡΠΎΡΠΈΠ»ΠΈ Π² ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΡΠ° Π½Π° ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΠΈΡ Π°ΡΡΡΠΈΡ(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2011-03) ΠΠΈΠ»Π°Π½ΠΎΠ²Π°/Milanova, Π./V.; Π’ΠΎΠ½ΡΠ΅Π²Π°/Toncheva, Π./A.; ΠΠ²Π°Π½ΠΎΠ²ΡΠΊΠ°/Ivanovska, Π./N.; ΠΠΈΠΌΠΈΡΡΠΎΠ²Π°/Dimitrova, Π./P.Π Π΅Π·ΡΠΌΠ΅. Π Π΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΠΈΡΡ Π°ΡΡΡΠΈΡ (PA) Π΅ Ρ ΡΠΎΠ½ΠΈΡΠ½ΠΎ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎ Π²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΎ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅ Ρ Π½Π΅ΠΈΠ·ΡΡΠ½Π΅Π½Π° Π΅ΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡ, ΠΊΠΎΠ΅ΡΠΎ Π²ΠΎΠ΄ΠΈ Π΄ΠΎ ΠΏΠΎΡΡΠ΅ΠΏΠ΅Π½Π½ΠΎ ΡΠ°Π·ΡΡΡΠ°Π²Π°Π½Π΅ Π½Π° ΡΡΠ°Π²ΠΈΡΠ΅ ΠΈ Π½Π° ΠΏΠ΅ΡΠΈΡΡΠ°Π²Π½ΠΈΡΠ΅ ΡΡΡΡΠΊΡΡΡΠΈ. ΠΡΠΈΡΠΊΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΠΈ ΡΡΠ°ΡΡΠ½ΠΈΡΠΈ Π½Π° ΠΈΠΌΡΠ½Π½ΠΈΡ ΠΎΡΠ³ΠΎΠ²ΠΎΡ ΠΈΠ³ΡΠ°ΡΡ ΡΠΎΠ»Ρ ΠΏΡΠΈ ΠΈΠ½ΠΈΡΠΈΠΈΡΠ°Π½Π΅ΡΠΎ, ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΡΠΎ ΠΈ ΠΏΠΎΠ΄Π΄ΡΡΠΆΠ°Π½Π΅ΡΠΎ Π½Π° Π°Π²ΡΠΎΠΈΠΌΡΠ½Π½ΠΈΡ ΠΏΡΠΎΡΠ΅Ρ ΠΏΡΠΈ Π Π. Π‘ΠΈΠ½Ρ ΡΠΎΠ½ΠΈΠ·ΠΈΡΠ°Π½Π΅ΡΠΎ Π½Π° ΠΊΠ»Π΅ΡΡΡΠ½ΠΈΡ ΠΎΡΠ³ΠΎΠ²ΠΎΡ ΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡΡΠ° Π½Π° ΡΠΈΡΠΎΠΊΠΈΠ½ΠΈ ΠΏΡΠΈ Π΄Π΅ΡΡΡΡΠΊΡΠΈΡ Π½Π° ΠΊΠΎΡΡΡΠ° Π΅ Π΄ΠΎΡΡΠ° ΡΠ»ΠΎΠΆΠ½ΠΎ. Π ΠΎΠ±Π·ΠΎΡΠ° ΡΠ΅ ΠΎΠ±ΡΡΠΆΠ΄Π°Ρ Π½ΠΎΠ²ΠΈΡΠ΅ Π΄Π°Π½Π½ΠΈ ΠΎΡΠ½ΠΎΡΠ½ΠΎ ΡΠΎΠ»ΡΡΠ° Π½Π° Π½Π΅ΡΡΡΠΎΡΠΈΠ»ΠΈΡΠ΅ Π² ΠΏΠ°ΡΠΎΠ³Π΅- Π½Π΅Π·Π°ΡΠ° Π½Π° ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΠΈΡ Π°ΡΡΡΠΈΡ. Π’Π΅ ΠΌΠΎΠ³Π°Ρ Π΄Π° Π΅ΠΊΡΠΏΡΠ΅ΡΠΈΡΠ°Ρ ΠΌΠ΅ΠΌΠ±ΡΠ°Π½Π½ΠΎ ΡΠ²ΡΡΠ·Π°Π½ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΎΡ Π½Π° ΡΠ΄ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΡΠΎΡ ΞΊΠ Π»ΠΈΠ³Π°Π½Π΄ (RANKL), ΡΠ΅ΡΠ΅ΠΏΡΠΎΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΎΡ Π½Π° ΡΠ΄ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΡΠΎΡ ΞΊΠ (RANK) ΠΈ ΠΎΡΡΠ΅ΠΎΠΏΡΠΎΡΠ΅Π³Π΅ΡΠΈΠ½ (OPG), ΠΊΠΎΠ΅ΡΠΎ Π³ΠΈ ΠΏΡΠ°Π²ΠΈ Π²Π°ΠΆΠ½ΠΈ ΡΠ°ΠΊΡΠΎΡΠΈ Π·Π° ΠΎΡΡΠ΅ΠΎΠΊΠ»Π°ΡΡΠΎΠ³Π΅Π½Π΅Π·Π°ΡΠ°. ΠΠ΅ΡΡΡΠΎΡΠΈΠ»ΠΈΡΠ΅ ΠΌΠΎΠ³Π°Ρ Π΄Π° ΡΡΠ°ΡΡΠ²Π°Ρ ΠΈ Π² ΡΠ½ΠΈΠΊΠ°Π»Π΅Π½ ΡΠ΅Π³ΡΠ»Π°ΡΠΎΡΠ΅Π½ ΠΊΡΡΠ³ Π·Π° ΡΠΈΠ½ΡΠ΅Π· ΠΈ ΠΎΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π°Π²Π°Π½Π΅ Π½Π° Π²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΈΡ ΡΠΈΡΠΎΠΊΠΈΠ½ IL-17. ΠΡΠΈ Π Π ΡΠ° ΠΎΡΠΊΡΠΈΡΠΈ Π½ΡΠΊΠΎΠΈ ΠΎΡΠΊΠ»ΠΎΠ½Π΅Π½ΠΈΡ ΠΏΡΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡΡΠ° ΠΈ ΡΠ΅Π³ΡΠ»Π°ΡΠΈΡΡΠ° Π½Π° ΠΈΠ½ΡΠ΅ΡΠ»Π΅Π²ΠΊΠΈΠ½-17 (IL-17). ***** Summary. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease with unknown etiology which results in the destruction of cartilage and bone. All main immunological components play a fundamental role in the initiation, dissemination and perpetuation of autoimmune process in RA. The precise control of cellular and immunological events leading to bone destruction is complex. In the present review, new evidences about the role of neutrophils in the pathogenesis of RA will be discussed. Neutrophils can express membraneβbound RANKL, RANK and OPG that determines them as important factors in osteoclastogenesis. They also can participate in the unique regulatory loop for synthesis and release of pro-inflammatory IL-17. Disturbance of the production and regulation of IL-17 has been observed in RA.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡOΠΏΠΈΠΎΠΈΠ΄Π½ΠΈ Π°Π½Π°Π»Π³Π΅ΡΠΈΡΠΈ ΡΡΠ΅ΡΡ Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΈ ΡΡΠ΅Π΄ΡΡΠ²Π°. ΠΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ΡΠΎ ΠΈΠΌ ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π° Π±ΠΎΠ»ΠΊΠ°ΡΠ° ΠΏΡΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ½ΠΈΡΠ΅ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2012-11) ΠΠΎΡΠ΄ΠΆΠΈΠ΅Π²Π°/Boyadzhieva, Π./V.; Π‘ΡΠΎΠΈΠ»ΠΎΠ²/Stoilov, Π ./R.; Π Π°ΡΠΊΠΎΠ²/Rashkov, Π ./R.; ΠΠΎΠ»Π°ΡΠΎΠ²/Kolarov, ΠΠ»./Zl.ΠΠΎΠ»ΠΊΠ°ΡΠ° Π΅ ΡΠ½ΠΈΠ²Π΅ΡΡΠ°Π»Π΅Π½ Π±ΠΎΠ»Π΅ΡΡΠ΅Π½ ΡΠΈΠΌΠΏΡΠΎΠΌ. Π’Ρ Π΅ Π΅Π΄ΠΈΠ½ ΠΎΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈΡΠ΅ Π·Π° ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎΡΠΎ Π½Π° ΠΆΠΈΠ²ΠΎΡΠ° ΠΈ Π·Π΄ΡΠ°Π²Π½ΠΎΡΠΎ Π±Π»Π°Π³ΠΎΠΏΠΎΠ»ΡΡΠΈΠ΅ Π½Π° ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄Π°. ΠΠΎΠ²Π»ΠΈΡΠ²Π°Π½Π΅ΡΠΎ ΓΉ Π΅ ΠΎΡΠ½ΠΎΠ²Π½Π° ΡΠ΅Π» Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ Π½Π° Π²ΡΡΠΊΠΎ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅. ΠΠ°ΠΉ-ΡΠ΅ΡΡΠΎ ΡΠΏΠΎΡΡΠ΅Π±ΡΠ²Π°Π½ΠΈΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΈ Π·Π° ΠΎΠ²Π»Π°Π΄ΡΠ²Π°Π½Π΅ Π½Π° Π±ΠΎΠ»ΠΊΠΎΠ²Π°ΡΠ° ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΠΊΠ° ΡΠ° Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΠΈΡΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΈ ΡΡΠ΅Π΄ΡΡΠ²Π° (ΠΠ‘ΠΠΠ‘) Π²ΠΊΠ»ΡΡΠΈΡΠ΅Π»Π½ΠΎ COX2 ΠΈΠ½Ρ ΠΈΠ±ΠΈΡΠΎΡΠΈΡΠ΅. ΠΠΎ-ΡΡΠ΄ΠΊΠΎ ΡΠ΅ ΠΈΠ·ΠΏΠΎΠ»Π·Π²Π°Ρ ΠΎΠΏΠΈΠΎΠΈΠ΄Π½ΠΈΡΠ΅ Π°Π½Π°Π»Π³Π΅ΡΠΈΡΠΈ ΠΏΠΎΡΠ°Π΄ΠΈ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡΠ° Π·Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π½Π° ΡΠΎΠ»Π΅ΡΠ°Π½ΡΠ½ΠΎΡΡ ΠΈ ΠΏΡΠΈΡΡΡΠ°ΡΡΡΠ²Π°Π½Π΅ ΠΊΡΠΌ ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΈΡΠ΅. ΠΠ° ΡΠ°Π·Π»ΠΈΠΊΠ° ΠΎΡ Π½Π°ΡΠΊΠΎΡΠΈΡΠ½ΠΈΡΠ΅ Π°Π½Π°Π»Π³Π΅ΡΠΈΡΠΈ ΠΠ‘ΠΠΠ‘ Π½Π΅ ΠΏΠΎΡΠΈΡΠΊΠ°Ρ Π΄ΠΈΡ Π°ΡΠ΅Π»Π½ΠΈΡ ΡΠ΅Π½ΡΡΡ, Π½Π΅ ΠΏΡΠ΅Π΄ΠΈΠ·Π²ΠΈΠΊΠ²Π°Ρ Π΅ΡΡΠΎΡΠΈΡ ΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π° Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡ, ΠΊΠΎΠ΅ΡΠΎ Π³ΠΈ ΠΏΡΠ°Π²ΠΈ ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½Ρ Π½Π° ΠΏΡΡΠ²ΠΈ ΠΈΠ·Π±ΠΎΡ ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π° Π±ΠΎΠ»ΠΊΠΎΠ²ΠΈΡ ΡΠΈΠΌΠΏΡΠΎΠΌ ΠΏΡΠΈ Π²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΈΡΠ΅ ΠΈ Π΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΠΈΡΠ΅ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ. Π‘ΡΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΈΡΠ΅ ΡΡ Π²Π°ΡΠ°Π½ΠΈΡ ΠΈΠ·ΠΈΡΠΊΠ²Π°Ρ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π° ΠΎΡΡΡΠ°ΡΠ° ΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ½Π°ΡΠ° Π±ΠΎΠ»ΠΊΠ° Ρ Π²ΡΠΈΡΠΊΠΈ Π²ΡΠ·ΠΌΠΎΠΆΠ½ΠΈ ΡΡΠ΅Π΄ΡΡΠ²Π°, Π²ΠΊΠ»ΡΡΠΈΡΠ΅Π»Π½ΠΎ ΠΈ Ρ Π½Π°ΡΠΊΠΎΡΠΈΡΠ½ΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΈ. Π’ΠΎΠ²Π° Π½ΠΈ ΠΊΠ°ΡΠ° Π΄Π° Π·Π°Π΄Π°Π΄Π΅ΠΌ Π²ΡΠΏΡΠΎΡΠ°: βKΠΎΠ³Π° Π΅ ΠΌΠΎΠΌΠ΅Π½ΡΡΡ Π΄Π° ΠΏΡΠΈΠ±Π΅Π³Π½Π΅ΠΌ ΠΊΡΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Ρ Π½Π°ΡΠΊΠΎΡΠΈΡΠ½ΠΈ Π°Π½Π°Π»Π³Π΅ΡΠΈΡΠΈ ΠΈ ΠΊΠΎΠ»ΠΊΠΎ Π²ΡΠ΅ΠΌΠ΅ Π΄Π° ΠΏΡΠΎΠ΄ΡΠ»ΠΆΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΡΡΠ° Ρ ΡΡΡ ?β. ****** Summary. Pain is a universal disease symptom. It is one of the factors that determines the quality of life and the well-being of the individual. Pain management is a key goal in treating any form of disease. The most commonly used pain-managing substances are the NSAIDs, including the COX2 inhibitors. The opioid analgesics are more rarely used due to the likelihood of developing tolerance-building and addiction to the medications. In contrast to opioids, NSAIDs do not suppress the respiratory center and do not cause euphoria and drug addiction, which makes them first-choice medications for treating pain symptoms in inflammatory and degenerative diseases. Contemporary concepts emphasize on treatment of acute and chronic pain by all possible means, including opiod substances. This makes us pose the question, βWhen is the right time to start using opiod analgesics and how long should the therapy last?β
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡSimponi (Golimumab) β Π½ΠΎΠ²Π° Π²ΡΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡ Π² Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ Π½Π° Π²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΈΡΠ΅ ΡΡΠ°Π²Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2011-03) Π¨Π΅ΠΉΡΠ°Π½ΠΎΠ²/Sheytanov, Π./I.; Π Π°ΡΠΊΠΎΠ²/Rashkov, Π ./R.; ΠΠ΅ΡΡΠ°Π½ΠΎΠ²Π°/Petranova, Π¦Π²./Tsv.Π Π΅Π·ΡΠΌΠ΅. ΠΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΈΡΠ΅ ΡΡΠ°Π²Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ ΡΠ° Ρ Π²ΠΈΡΠΎΠΊΠ° ΡΠ΅ΡΡΠΎΡΠ° ΠΈ ΡΡΡ Π·Π½Π°ΡΠΈΠΌΠΈ ΡΠΎΡΠΈΠ°Π»Π½ΠΈ ΠΈ ΠΈΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΠΈΡΠΈ. ΠΠ°ΡΡΠ³Π°Ρ ΠΏΡΠ΅Π΄ΠΈΠΌΠ½ΠΎ Ρ ΠΎΡΠ° Π² Π°ΠΊΡΠΈΠ²Π½Π° Π²ΡΠ·ΡΠ°ΡΡ, ΠΊΠ°ΡΠΎ Π°Π³ΡΠ΅ΡΠΈΠ²Π½ΠΈΡΡ Ρ ΠΎΠ΄ Π½Π° ΠΏΡΠΎΡΠΈΡΠ°Π½Π΅ Π²ΠΎΠ΄ΠΈ Π΄ΠΎ Π΄ΡΠ»Π³ΠΎΡΡΠΎΡΠ½Π° Π·Π°Π³ΡΠ±Π° Π½Π° ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡΠ° ΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°ΡΠΈΡ, ΠΊΠΎΡΡΠΎ Π² ΡΠ΅ΠΆΠΊΠΈΡΠ΅ ΡΠ»ΡΡΠ°ΠΈ Π΅ Π΄ΠΎ ΠΊΡΠ°Ρ Π½Π° ΠΆΠΈΠ²ΠΎΡΠ°. ΠΡΠ΅Π· ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΎΡΠΎ Π΄Π΅ΡΠ΅ΡΠΈΠ»Π΅ΡΠΈΠ΅ TNF-Π°Π»ΡΠ° ΠΈΠ½Ρ ΠΈΠ±ΠΈΡΠΎΡΠΈΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π²Π°Ρ ΠΌΠ½ΠΎΠ³ΠΎ Π΄ΠΎΠ±ΡΠ° ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½Π° Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ Π·Π° ΠΏΠΎΠ²Π»ΠΈΡΠ²Π°Π½Π΅ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅, ΡΡΡΠ°Π΄Π°ΡΠΈ ΠΎΡ Ρ ΡΠΎΠ½ΠΈΡΠ½ΠΈ Π²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΈ ΡΡΠ°Π²Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ. ΠΠΎΠ΄ΡΡ Π΄ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎ ΠΏΠΎΠ΄ΠΎΠ±ΡΠ΅Π½ΠΈΠ΅ Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΡΠ½ΠΈΡΠ΅ ΡΠΈΠΌΠΏΡΠΎΠΌΠΈ Π½Π° ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΠΈΡ Π°ΡΡΡΠΈΡ (Π Π), ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ½ΠΈΡ Π°ΡΡΡΠΈΡ (ΠΡΠ) ΠΈ Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΠ°ΡΠΈΡ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡ (ΠΠ‘), Π·Π°Π±Π°Π²ΡΡ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²Π°ΡΠ° ΠΏΡΠΎΠ³ΡΠ΅ΡΠΈΡ Π½Π° ΡΠ΅Π·ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ, Π° ΡΠ°ΠΊΠ° ΡΡΡΠΎ ΠΏΠΎΠ΄ΠΎΠ±ΡΡΠ²Π°Ρ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠ°ΡΠ° ΡΡΠ½ΠΊΡΠΈΡ ΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎΡΠΎ Π½Π° ΠΆΠΈΠ²ΠΎΡ ΠΏΡΠΈ Π±ΠΎΠ»Π½ΠΈΡΠ΅. Π ΠΎΠ±Π·ΠΎΡΠ° Π΅ Π½Π°ΠΏΡΠ°Π²Π΅Π½ ΠΏΡΠ΅Π³Π»Π΅Π΄ Π½Π° ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½Π°ΡΠ° Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π° Π½Π° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ Π½Π° Π½ΠΎΠ²ΠΈΡ TNF-Π°Π»ΡΠ° ΠΈΠ½Ρ ΠΈΠ±ΠΈΡΠΎΡ Simponi (Golimumab) ΠΏΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ Ρ Π Π, ΠΡΠ ΠΈ Π±ΠΎΠ»Π΅ΡΡ Π½Π° ΠΠ΅Ρ ΡΠ΅ΡΠ΅Π². ΠΠ°ΠΏΡΠ°Π²Π΅Π½ΠΎ Π΅ Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΡΠΎ, ΡΠ΅ Simponi (Golimumab) Π΅ Π½Π°Π΄Π΅ΠΆΠ΄Π½Π° ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½Π° Π°Π»ΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π° Π½Π° ΠΎΡΡΠ°Π½Π°Π»ΠΈΡΠ΅ TNF-Π°Π»ΡΠ° Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΈ, ΠΊΠ°ΡΠΎ ΡΠ΄ΠΎΠ±Π½ΠΈΡΡ Π½Π°ΡΠΈΠ½ Π½Π° ΠΏΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅, Π΅Π΄Π½Π° ΠΏΠΎΠ΄ΠΊΠΎΠΆΠ½Π° Π°ΠΏΠ»ΠΈΠΊΠ°ΡΠΈΡ Π²Π΅Π΄Π½ΡΠΆ ΠΌΠ΅ΡΠ΅ΡΠ½ΠΎ, ΠΎΡΠΈΠ³ΡΡΡΠ²Π° Π΅ΡΠ΅ΠΊΡΠΈΠ²Π΅Π½ ΠΊΠΎΠ½ΡΡΠΎΠ» Π½Π° Π±ΠΎΠ»Π΅ΡΡΡΠ° Ρ ΠΏΠΎ-ΠΌΠ°Π»ΠΊΠ° ΡΠ΅ΡΡΠΎΡΠ° Π½Π° ΠΈΠ½ΠΆΠ΅ΠΊΡΠΈΡΠ°Π½Π΅ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Ρ Π΄ΡΡΠ³ΠΈΡΠ΅ Π½Π°Π»ΠΈΡΠ½ΠΈ Π½Π° ΠΏΠ°Π·Π°ΡΠ° TNF-Π°Π»ΡΠ° ΠΈΠ½Ρ ΠΈΠ±ΠΈΡΠΎΡΠΈ. ***** Summary. Inflammatory joint diseases express high rate of incidence and the consequences of them are with social and economical significance. Affected are middle-aged individuals and the aggressive development of the disease leads to loss of working capacity and life-long invalidisation. During the last decade, TNFΞ± inhibitors showed good therapeutic efficacy in help of some patients to cope with the chronic disease. That class of drugs improve clinical outcome in patients with rheumatoid or psoriatic arthritis, and with ankylosing spondylitis. The progression of the disease is decreased due to data from roentgenographic examination, and quality of life is improved. Reviewed are the effects of the new TNFΞ± inhibitor Simponi (Golimumab) in patients with rheumatoid arthritis, psoriatic arthritis, and Bechterew's Disease (ankylosing spondylitis). The conclusion is that Simponi is a reliable alternative of the other TNFΞ± inhibitors. It has a comparatively acceptable way of usage (subcutaneous application once monthly) offering an effective control of the disease.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡSocial and professional identification of dentists in Bulgaria by the late 90th.(1999-09-04) ΠΠ°ΡΡΠΎΠ²Π°, ΠΠΈΠ΄ΠΈΡ // Katrova, LydiaThe purpose of the study was to determine the influence of the radically changing social environment in Bulgaria (1989-1997) on the socio-professional identification of dentists and its impact on the dental profession.. Methods: A sociological investigation was carried out involving a sample of 842 dentists (12%) from the total of 7129 dentists, working as follows: 42% in the salaried public sector, 30% in mixed setting - public sector and private practice and 28% - entirely in private practice. Questionnaire completed by 86% of the interviewed was focused on: 1.The structure of the Oral Health Service; 2.The professional profile of dentists; 3.The professional and social mobility of dentists; 4. The attitudes of dentists towards the current state of Dental education and Dental Service. The data had been treated statistically using SPSS package including Cramer test, alternative analyses (U-test), X sq. with p<0,05 and n=1,96. The level of satisfaction had been assessed according to the type of practice. The verbal answers were treated using content analysis. Results: Almost all dentists had started their career as salaried, but 43% left the public sector immediately after the legislative changes (V=0,434) and > 50% now were working under private contracts (0,494). Most of dentists work 5 days in the week - 90% (V=0,275), 6-7 hours per diem (V=0,546) and go in holiday usually for 3 weeks. They work mostly as general practitioners (V-0,264), only 25% of salaried, 17% of mixed and 12,6% of private practices deliver exclusively specialized care (V=0,682). 35% of dentists would spend 1-3% of their annual income and up to 2 weeks for continuing education (0,237). Private practitioners showed the highest level of satisfaction with their profession (97%) versus 80% of salaried dentists. The majority valued the quality of undergraduate dental education (74%), but only 25% considered postgraduate education and vocational training to be very good. Conclusions: We conclude that the dentists in Bulgaria by the late 90th tend to identify themselves as liberal practitioners within the pluralistic model of oral health care delivery which influences their expectations for an adecuate dental education.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡSystemic lupus erythematosus ΠΈ Π°Π½Π΄ΡΠΎΠ³Π΅Π½ΠΈ(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2011-06) Π’Π°Π½Π΅Π²/Tanev, Π./D.; Π ΠΎΠ±Π΅Π²Π°/Robeva, Π ./R.; Π’ΠΎΠΌΠΎΠ²Π°/Tomova, Π./A.; ΠΡΠΌΠ°Π½ΠΎΠ²/Kumanov, Π€./Ph.; Π Π°ΡΠΊΠΎΠ²/Rashkov, Π ./R.; ΠΠΎΠ»Π°ΡΠΎΠ²/Kolarov, ΠΠ»./Zl.Π Π΅Π·ΡΠΌΠ΅. Systemic lupus erythematosus (Π‘ΠΠ) Π΅ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅ Π½Π° ΡΡΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»Π½Π°ΡΠ° ΡΡΠΊΠ°Π½, ΠΊΠΎΠ΅ΡΠΎ Π·Π°ΡΡΠ³Π° ΠΌΠ½ΠΎΠ³ΠΎΠΊΡΠ°ΡΠ½ΠΎ ΠΏΠΎ-ΡΠ΅ΡΡΠΎ ΠΆΠ΅Π½ΠΈΡΠ΅ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Ρ ΠΌΡΠΆΠ΅ΡΠ΅. ΠΠΎΡΠ°Π΄ΠΈ ΡΠΎΠ²Π° ΡΠ΅ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°, ΡΠ΅ Π°Π½Π΄ΡΠΎΠ³Π΅Π½ΠΈΡΠ΅ Π²Π»ΠΈΡΡΡ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»Π½ΠΎ Π²ΡΡΡ Ρ Π°Π²ΡΠΎΠΈΠΌΡΠ½Π½ΠΈΡ ΠΏΡΠΎΡΠ΅Ρ. Π ΠΎΠ±Π·ΠΎΡΠ° ΡΠ° ΡΠ°Π·Π³Π»Π΅Π΄Π°Π½ΠΈ ΡΡΡΠ΅ΡΡΠ²ΡΠ²Π°ΡΠΈΡΠ΅ Π΄Π°Π½Π½ΠΈ Π·Π° Π²ΡΡΠ·ΠΊΠ°ΡΠ° ΠΌΠ΅ΠΆΠ΄Ρ ΠΌΡΠΆΠΊΠΈΡΠ΅ ΠΏΠΎΠ»ΠΎΠ²ΠΈ Ρ ΠΎΡΠΌΠΎΠ½ΠΈ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ½ΠΈΡΠ΅ ΠΏΡΠΎΡΠ²ΠΈ Π½Π° ΡΠΈΡΡΠ΅ΠΌΠ½ΠΈΡ Π»ΡΠΏΡΡ. ΠΠ·ΡΠ»Π΅Π΄Π²Π°Π½ΠΈΡΡΠ° Π²ΡΡΡ Ρ ΠΎΠΏΠΈΡΠ½ΠΈ ΠΌΠΎΠ΄Π΅Π»ΠΈ Π½Π° Π‘ΠΠ ΠΏΠΎΠΊΠ°Π·Π²Π°Ρ, ΡΠ΅ ΠΏΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ΡΠΎ Π½Π° ΡΠ΅ΡΡΠΎΡΡΠ΅ΡΠΎΠ½ ΠΈ ΠΠ₯ΠΠΠ‘ Π½Π°ΠΌΠ°Π»ΡΠ²Π° ΡΠΈΠ½ΡΠ΅Π·Π° Π½Π° Π°Π½ΡΠΈΡΠ΅Π»Π°, ΠΏΡΠ΅Π΄ΠΏΠ°Π·Π²Π° Π±ΠΎΠ»Π½ΠΈΡΠ΅ ΠΆΠΈΠ²ΠΎΡΠ½ΠΈ ΠΎΡ Π±ΡΡΠ·Π° ΠΏΡΠΎΠ³ΡΠ΅ΡΠΈΡ Π½Π° Π±ΠΎΠ»Π΅ΡΡΡΠ° ΠΈ ΡΠ΄ΡΠ»ΠΆΠ°Π²Π° ΠΏΡΠ΅ΠΆΠΈΠ²ΡΠ΅ΠΌΠΎΡΡΡΠ°. ΠΡΠΈ Ρ ΠΎΡΠ° Π²Π»ΠΈΡΠ½ΠΈΠ΅ΡΠΎ Π½Π° Π°Π½Π΄ΡΠΎΠ³Π΅Π½ΠΈΡΠ΅ Π΅ ΠΈΠ·ΡΠ»Π΅Π΄Π²Π°Π½ΠΎ ΠΏΡΠ΅Π· ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡΠ΅ 30 Π³ΠΎΠ΄ΠΈΠ½ΠΈ, Π½ΠΎ ΡΠ΅Π·ΡΠ»ΡΠ°ΡΠΈΡΠ΅ ΡΠ° ΠΏΡΠΎΡΠΈΠ²ΠΎΡΠ΅ΡΠΈΠ²ΠΈ. ΠΠΎΠ½ΠΈΠΆΠ΅Π½ΠΈ Π½ΠΈΠ²Π° Π½Π° ΡΠ΅ΡΡΠΎΡΡΠ΅ΡΠΎΠ½Π° ΠΈ ΠΠ₯ΠΠΠ‘ ΡΠ° Π½Π°Π±Π»ΡΠ΄Π°Π²Π°Π½ΠΈ ΠΊΠ°ΠΊΡΠΎ Ρ ΠΌΡΠΆΠ΅ΡΠ΅, ΡΠ°ΠΊΠ° ΠΈ Ρ ΠΆΠ΅Π½ΠΈΡΠ΅ Ρ Π»ΡΠΏΡΡ. ΠΠ΅ Π΅ ΡΡΡΠ°Π½ΠΎΠ²Π΅Π½ΠΎ ΠΊΠ°ΠΊ ΡΠ΅Π·ΠΈ ΠΏΡΠΎΠΌΠ΅Π½ΠΈ Π²Π»ΠΈΡΡΡ Π½Π° Π°Π²ΡΠΎΠΈΠΌΡΠ½Π½ΠΈΡ ΠΏΡΠΎΡΠ΅Ρ. ΠΠ΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΈ ΡΠ° Π΄ΠΎΠΏΡΠ»Π½ΠΈΡΠ΅Π»Π½ΠΈ ΠΈΠ·ΡΠ»Π΅Π΄Π²Π°Π½ΠΈΡ, ΠΊΠΎΠΈΡΠΎ Π΄Π° ΠΈΠ·ΡΡΠ½ΡΡ Π²ΡΡΠ·ΠΊΠ°ΡΠ° ΠΌΠ΅ΠΆΠ΄Ρ Π°Π½Π΄ΡΠΎΠ³Π΅Π½ΠΈΡΠ΅, ΠΈΠΌΡΠ½Π½Π°ΡΠ° ΡΠΈΡΡΠ΅ΠΌΠ° ΠΈ Π‘ΠΠ ΠΏΡΠΈ Ρ ΠΎΡΠ° ΠΈ ΡΠ»Π΅Π΄ ΡΠΎΠ²Π° Π΄Π° ΡΠ΅ ΠΏΡΠΎΡΡΠ°Ρ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»Π½ΠΈΡΠ΅ Π²ΡΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΈ ΡΡΡΠ°Π½ΠΈΡΠ½ΠΈΡΠ΅ Π΅ΡΠ΅ΠΊΡΠΈ ΠΎΡ ΠΏΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ΡΠΎ Π½Π° Π΅ΠΊΠ·ΠΎΠ³Π΅Π½Π½ΠΈ ΡΡΠ΅ΡΠΎΠΈΠ΄ΠΈ ΠΏΡΠΈ Π±ΠΎΠ»Π½ΠΈ ΡΡΡ ΡΠΈΡΡΠ΅ΠΌΠ΅Π½ Π»ΡΠΏΡΡ. ***** Summary. Systemic lupus erythematosus (SLE) is an autoimmune disease that affects mainly women,while the prevalence in men is very low. Therefore, a protective role of the androgens on the autoimmune process has been suggested. In this review, the existing data about the relationships between male sex hormones and clinical signs of systemic lupus have been discussed. The studies in experimental SLE models have shown that the application of testosterone and DHEAS decreases the antibody production, protects the animals from a rapid SLE progression and increases their longevity. In humans, the influence of the androgens has been studied for the last thirty years, but the conclusions are still inconsistent. Decreased levels of testosterone and DHEAS have been found in men and women with lupus. However, it is not clarified, how these changes affect the autoimmune process. Further investigations are necessary to reveal the interrelations between androgens, immune system and SLE in humans. The results could help the development of new androgen-based therapeutic strategies considering possible benefits and expected side effects.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΠ»Π΅ΡΠ³ΠΈΡ ΠΏΠΎ Π²ΡΠ΅ΠΌΠ΅ Π½Π° Π°Π½Π΅ΡΡΠ΅Π·ΠΈΡ ΠΈ Π½Π΅ΠΉΠ½ΠΎΡΠΎ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ°Π½Π΅(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library - MU Sofia, 2009-01) ΠΠ΅Π½ΠΎΠ²Π° / Genova, Π‘. / S.; ΠΠ΅Π½ΠΎΠ²Π° /Genova, Π. / E.ΠΠ½Π°ΡΠΈΠ»Π°ΠΊΡΠΈΡΡΠ° Π΅ ΡΠ΅ΠΆΠΊΠ° IgE-ΠΌΠ΅Π΄ΠΈΠΈΡΠ°Π½Π° Π°Π»Π΅ΡΠ³ΠΈΡΠ½Π° ΡΠ΅Π°ΠΊΡΠΈΡ, ΠΏΡΠΈΡΠΈΠ½Π΅Π½Π° ΠΎΡ Π²Π°Π·ΠΎΠ°ΠΊΡΠΈΠ²Π½ΠΈ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ, ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈ ΠΎΡ ΠΌΠ°ΡΡΠΎΡΠΈΡΠΈ ΠΈ Π±Π°Π·ΠΎΡΠΈΠ»ΠΈ, ΡΠ»Π΅Π΄ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎ ΠΈΠ·Π»Π°Π³Π°Π½Π΅ Π½Π° ΡΡΠΎΡΠ²Π΅ΡΠ½ΠΈΡ Π°Π½ΡΠΈΠ³Π΅Π½. ΠΠ»ΠΈΠ½ΠΈΡΠ½Π°ΡΠ° ΠΊΠ°ΡΡΠΈΠ½Π° Π²ΠΊΠ»ΡΡΠ²Π° Π΄ΠΈΡΡΠ·Π½ΠΎ Π·Π°ΡΠ΅ΡΠ²ΡΠ²Π°Π½Π΅, ΡΡΡΠΈΠΊΠ°ΡΠΈΡ, Ρ ΠΈΠΏΠΎΡΠΎΠ½ΠΈΡ, ΡΠ°Ρ ΠΈΠΊΠ°ΡΠ΄ΠΈΡ, Π±ΡΠΎΠ½Ρ ΠΎΡΠΏΠ°Π·ΡΠΌ, ΡΡΡΠ΄Π΅ΡΠ΅Π½ Π°ΡΠ΅ΡΡ. Π’Ρ ΠΌΠΎΠΆΠ΅ Π΄Π° ΡΠ΅ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠ° ΠΏΠΎ Π²ΡΠ΅ΠΌΠ΅ Π½Π° Π°Π½Π΅ΡΡΠ΅Π·ΠΈΡ, Π½ΠΎ Π±ΡΡΠ·ΠΎ ΠΏΠΎΡΡΠ°Π²Π΅Π½Π°ΡΠ° Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π° ΠΈ ΠΏΡΠ°Π²ΠΈΠ»Π½ΠΎΡΠΎ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π²ΠΎΠ΄ΡΡ Π΄ΠΎ ΡΡΠΏΠ΅ΡΠ½ΠΎΡΠΎ ΠΎΠ²Π»Π°Π΄ΡΠ²Π°Π½Π΅. ΠΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ½ΠΈΡΠ΅ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΡ ΠΏΡΠ΅Π΄ΠΈ Π°Π½Π΅ΡΡΠ΅Π·ΠΈΡ ΡΠ° Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΈ ΠΏΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ Ρ Π°Π»Π΅ΡΠ³ΠΈΡΠ½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ. ***** Anaphylaxis is an IgE mediated severe allergic reaction causing release of vasoactive substances from mast cells and basophils after re-exposure to an antigen. Signs and symptoms include flush, urticaria, hypotension, tachycardia, bronchospasm, cardio-respiratory arrest etc. It can occur at induction of anesthesia when multiple drugs are being administered, and prompt diagnosis with correct management is the key to a successful outcome. Prophylaxis before anesthesia is needed for allergic patients.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΠ½Π°Π»ΠΈΠ· Π½Π° Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΡΠ½Π°ΡΠ° ΠΏΡΠΈΠ½Π°Π΄Π»Π΅ΠΆΠ½ΠΎΡΡ Π½Π° Π±ΠΎΠ»Π½ΠΈΡΠ΅ Ρ ΠΌΡΡΠΊΡΠ»Π½Π° ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡΠ° Π½Π° ΡΡΠ°Π½Π΄Π°ΡΡΠ½Π° ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½Π° ΠΏΡΠ°ΠΊΡΠΈΠΊΠ°(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2011-06) ΠΠ°Π»ΠΈΠ½ΠΎΠ²Π°/Kalinova, Π./D.; Π Π°ΡΠΊΠΎΠ²/Rashkov, Π ./R.Π Π΅Π·ΡΠΌΠ΅. ΠΡΡΠΊΡΠ»Π½Π°ΡΠ° ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ Π²ΠΊΠ»ΡΡΠ²Π° ΡΠΈΡΠΎΠΊ ΡΠΏΠ΅ΠΊΡΡΡ ΠΎΡ Π±ΠΎΠ»Π΅ΡΡΠΈ, ΠΊΠΎΠΈΡΠΎ ΠΎΠ±ΡΠΎ ΡΠ΅ Π½Π°ΡΠΈΡΠ°Ρ ΠΌΠΈ- ΠΎΠΏΠ°ΡΠΈΠΈ. ΠΠΈΠΎΠΏΠ°ΡΠΈΠΈΡΠ΅ ΡΠ° ΠΊΠ»Π°ΡΠΈΡΠΈΡΠΈΡΠ°Π½ΠΈ Π² Π½ΡΠΊΠΎΠ»ΠΊΠΎ ΠΎΡΠ½ΠΎΠ²Π½ΠΈ Π³ΡΡΠΏΠΈ Π²ΡΠ· ΠΎΡΠ½ΠΎΠ²Π° Π½Π° Π΅ΡΠΈΠΎΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π°- ΡΠ°: ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ½ΠΈ Π²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ Π½Π° ΠΌΡΡΠΊΡΠ»ΠΈΡΠ΅ο οο ΠΌΠΈΠΎΠ·ΠΈΡΠΈ (ΠΠΠ), Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½ΠΎ ΠΈΠ½Π΄ΡΡΠΈ- ΡΠ°Π½ΠΈ, Π΅Π½Π΄ΠΎΠΊΡΠΈΠ½Π½ΠΈ, ΡΠΎΠΊΡΠΈΡΠ½ΠΈ, ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ½ΠΈ, ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ·Π½ΠΈ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΈ, ΠΌΡΡΠΊΡΠ»Π½ΠΈ Π΄ΠΈΡΡΡΠΎΡΠΈΠΈ. Π ΡΠ΅Π²- ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½Π°ΡΠ° ΠΏΡΠ°ΠΊΡΠΈΠΊΠ° Π΅ Π²Π°ΠΆΠ½ΠΎ Π΄Π° ΡΠ΅ Π΄ΠΈΡΠ΅ΡΠ΅Π½ΡΠΈΡΠ°Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈΡΠ΅ Π²ΠΈΠ΄ΠΎΠ²Π΅ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΈ, ΠΎΡ Π΅Π΄Π½Π° ΡΡΡΠ°Π½Π°, Π° ΠΎΡ Π΄ΡΡΠ³Π°ο οο Π΄Π° ΡΠ΅ ΡΠ°Π·Π³ΡΠ°Π½ΠΈΡΠ°Ρ ΠΎΡ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ½ΠΈΡΠ΅ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ, Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΈΡΠ°ΡΠΈ ΡΠ΅ Ρ ΠΌΡΡΠΊΡΠ»Π½Π° ΡΠ»Π°Π±ΠΎΡΡ, ΠΏΡΠΈΠ΄ΡΡΠΆΠ΅Π½Π° ΠΈΠ»ΠΈ Π½Π΅ Ρ ΠΌΠΈΠ°Π»Π³ΠΈΠΈ. Π¦Π΅Π»ΡΠ° Π½Π° ΠΈΠ·ΡΠ»Π΅Π΄Π²Π°Π½Π΅ΡΠΎ Π΅ Π΄Π° ΡΠ΅ Π½Π°ΠΏΡΠ°Π²ΠΈ Π°Π½Π°Π»ΠΈΠ· Π½Π° Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΡΠ½Π°ΡΠ° ΠΏΡΠΈΠ½Π°Π΄Π»Π΅ΠΆΠ½ΠΎΡΡ Π½Π° Π±ΠΎΠ»Π½ΠΈΡΠ΅ Ρ ΠΌΡΡΠΊΡΠ»Π½Π° ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡΠ° Π½Π° ΡΡΠ°Π½Π΄Π°ΡΡΠ½Π° ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½Π° ΠΏΡΠ°ΠΊΡΠΈΠΊΠ°. ΠΡΡ Π° ΠΏΡΠΎΡΠ»Π΅Π΄Π΅Π½ΠΈ 60 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈο οο 47 ΠΆΠ΅Π½ΠΈ ΠΈ 13 ΠΌΡΠΆΠ΅. ΠΡΠΈ ΠΏΠΎΡΡΠ°Π²ΡΠ½Π΅ Π½Π° Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π°ΡΠ° Π±ΡΡ Π° ΠΈΠ·ΠΏΠΎΠ»Π·Π²Π°Π½ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ½ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈ. Π£ΡΡΠ°Π½ΠΎΠ²ΠΈΡ ΠΌΠ΅ ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ½ΠΈ Π²ΡΠ·ΠΏΠ°Π»ΠΈ- ΡΠ΅Π»Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ Π½Π° ΠΌΡΡΠΊΡΠ»ΠΈΡΠ΅ ΠΏΡΠΈ 64,9% ΠΎΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅; ΠΌΡΡΠΊΡΠ»Π½ΠΈ Π΄ΠΈΡΡΡΠΎΡΠΈΠΈο οο ΠΏΡΠΈ 6,7%; Π΅Π½- Π΄ΠΎΠΊΡΠΈΠ½Π½ΠΈ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΈο οο ΠΏΡΠΈ 5%; Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½ΠΈ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΈο οο ΠΏΡΠΈ 5%; ΡΠΎΠΊΡΠΈΡΠ½ΠΈ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΈο οο ΠΏΡΠΈ 1,7%; Π²ΠΈ- ΡΡΡΠ½ΠΈ ΠΌΠΈΠΎΠ·ΠΈΡΠΈο οο ΠΏΡΠΈ 10%; ΠΌΠΈΠ°ΡΡΠ΅Π½Π΅Π½ ΡΠΈΠ½Π΄ΡΠΎΠΌ Eaton-Lambertο οο ΠΏΡΠΈ 1,7%. Π‘ΡΠ΅Π΄ Π³ΡΡΠΏΠ°ΡΠ° Ρ ΠΈΠ΄ΠΈΠΎΠΏΠ°- ΡΠΈΡΠ½ΠΈ Π²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ Π½Π° ΠΌΡΡΠΊΡΠ»ΠΈΡΠ΅ Π±Π΅ΡΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΈΡΠ°Π½ Π΄Π΅ΡΠΌΠ°ΡΠΎΠΌΠΈΠΎΠ·ΠΈΡ (ΠΠ) ΠΏΡΠΈ 35,2% ΠΎΡ Π±ΠΎΠ»Π½ΠΈΡΠ΅; ΠΏΠΎΠ»ΠΈΠΌΠΈΠΎΠ·ΠΈΡ (ΠΠ)ο οο ΠΏΡΠΈ 29,7%; ΠΌΠΈΠΎΠ·ΠΈΡ, ΠΏΡΠΈΠΏΠΎΠΊΡΠΈΠ²Π°Ρ ΡΠ΅ Ρ Π΄ΡΡΠ³ΠΎ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎ Π·Π°Π±ΠΎ- Π»ΡΠ²Π°Π½Π΅ Π½Π° ΡΡΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»Π½Π°ΡΠ° ΡΡΠΊΠ°Π½ (overlap ΠΌΠΈΠΎΠ·ΠΈΡ),ο οο ΠΏΡΠΈ 27%; ΡΡΠΌΠΎΡ-Π°ΡΠΎΡΠΈΠΈΡΠ°Π½ ΠΌΠΈΠΎΠ·ΠΈΡο οο ΠΏΡΠΈ 8,1%. Π‘ΡΠ΅Π΄ Π΄ΡΡΠ³ΠΈΡΠ΅ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ Ρ Π²ΠΎΠ΄Π΅ΡΠ° ΠΌΡΡΠΊΡΠ»Π½Π° ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ ΡΡΡΠ°Π½ΠΎΠ²ΠΈΡ ΠΌΠ΅ 3 Π±ΠΎΠ»Π½ΠΈ Ρ ΠΏΠΎΠ»ΠΈΠΌΠΈΠ°Π»Π³ΠΈΡ ΡΠ΅Π²ΠΌΠ°ΡΠΈΠΊΠ° ΠΈ 2-ΠΌΠ° β Ρ ΡΠΈΠ±ΡΠΎΠΌΠΈΠ°Π»Π³ΠΈΡ. ***** Summary. Muscle pathology includes broad spectrum diseases, which are refered to myopathies. Myopathies are classified in some main groups on the basis of etiopathogenesis β idiopathic inflammatory myopathiesο οο (IIM), drug-induced, endocrine, toxic, metabolic, infectious myopathies, muscle dystrophy. In the rheumatology practice, it is important to differentiate a variety of myopathies on one hand, as to mark off rheumatic diseases characterized by muscle weakness and/or myalgia on the other hand. Aim of the study was to analyse nosologic entity of patients with muscle pathology in the routine rheumatology practice. Sixty patients (47 women and 13 men) were enrolled in this study. Different diagnostic methods were used to diagnosticate the patients. There were determined IIM in 64.9% of patients; muscle dystrophies β 6,7%; endocrine myopathies β 5%; drug-induced myopathies β 5%; toxic myopathies β 1,7%; viral myositis β 10%; Eaton-Lambert myastenic syndrome β 1,7%. Among patients with IIM, there were diagnosed dermatomyositis (DM) in 35,2%; polymyositis (PM) β 29,7%; myositis associated with other systemic diseases (overlap myositis) β 27%; tumor-associated myositis β 8,1%. Among other rheumatic diseases with muscle pathology, three patients with polymyalgia rheumatica and two patients with fibromyalgia were diagnosed.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΠ½ΡΠΈΡΠΎΡΡΠΎΠ»ΠΈΠΏΠΈΠ΄Π΅Π½ ΡΠΈΠ½Π΄ΡΠΎΠΌ β ΠΈΡΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈ Π΄Π°Π½Π½ΠΈ, Π΅ΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π°(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2011-12) Π‘ΡΠΎΠΈΠ»ΠΎΠ²/Stoilov, Π./N.; Π Π°ΡΠΊΠΎΠ²/Rashkov, Π ./R.; Π‘ΡΠΎΠΈΠ»ΠΎΠ²/Stoilov, Π ./R.Π Π΅Π·ΡΠΌΠ΅. ΠΠ½ΡΠΈΡΠΎΡΡΠΎΠ»ΠΈΠΏΠΈΠ΄Π½ΠΈΡΡ ΡΠΈΠ½Π΄ΡΠΎΠΌ Π΅ Π°Π²ΡΠΎΠΈΠΌΡΠ½Π½ΠΎ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅, Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΈΡΠ°ΡΠΎ ΡΠ΅ Ρ ΡΠΈΡΠΊΡΠ»Π°ΡΠΈΡ Π½Π° Π°Π½ΡΠΈΡΠ΅Π»Π° ΡΡΠ΅ΡΡ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ ΡΠΎΡΡΠΎΠ»ΠΈΠΏΠΈΠ΄ΠΈ ΠΈ ΡΠ΅Ρ Π½ΠΈΡΠ΅ Π±Π΅Π»ΡΡΡΠ½ΠΈ ΠΊΠΎΡΠ°ΠΊΡΠΎΡΠΈ. ΠΡΠ½ΠΎΠ²Π½Π°ΡΠ° ΠΌΠ°Π½ΠΈΡΠ΅ΡΡΠ°ΡΠΈΡ Π½Π° Π°Π½ΡΠΈΡΠΎΡΡΠΎΠ»ΠΈΠΏΠΈΠ΄Π½ΠΈΡ ΡΠΈΠ½Π΄ΡΠΎΠΌ Π΅ ΡΡΠΎΠΌΠ±ΠΎΠ·Π°ΡΠ°. Π ΡΠΎΠ·ΠΈ ΠΏΡΠΎΡΠ΅Ρ Π²Π·Π΅ΠΌΠ°Ρ ΡΡΠ°ΡΡΠΈΠ΅ Π΅Π½Π΄ΠΎΡΠ΅Π»Π½ΠΈ ΠΊΠ»Π΅ΡΠΊΠΈ, ΠΌΠΎΠ½ΠΎΡΠΈΡΠΈ, ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΈ ΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΌΠ΅Π½Ρ. ΠΠ½Π΄ΠΎΡΠ΅Π»Π½ΠΈΡΠ΅ ΠΊΠ»Π΅ΡΠΊΠΈ ΠΈ ΠΌΠΎΠ½ΠΎΡΠΈΡΠΈΡΠ΅ ΠΌΠΎΠ³Π°Ρ Π΄Π° Π±ΡΠ΄Π°Ρ Π°ΠΊΡΠΈΠ²ΠΈΡΠ°Π½ΠΈ ΠΎΡ Π°Π½ΡΠΈΡΠ΅Π»Π°ΡΠ° ΡΡΠ΅ΡΡ Ξ²2GPI. Π Π΅Π΄ΠΈΡΠ° Π°Π²ΡΠΎΠΈΠΌΡΠ½Π½ΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ½ΠΈ Π±ΠΎΠ»Π΅ΡΡΠΈ, Π²ΠΊΠ». Π Π, Π‘ΠΠ ΠΈ ΠΠ€Π‘, ΡΠ΅ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΈΡΠ°Ρ Ρ Π°ΠΊΡΠ΅Π»Π΅ΡΠΈΡΠ°Π½Π° Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ·Π° ΠΈ ΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π½ΠΎ - Ρ ΠΏΠΎΠ²ΠΈΡΠ΅Π½ ΡΠΈΡΠΊ ΠΎΡ ΠΊΠ°ΡΠ΄ΠΈΠΎΠ²Π°ΡΠΊΡΠ»Π°ΡΠ½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ ΠΈ ΡΠΌΡΡΡΠ½ΠΎΡΡ. ΠΠ°ΡΠΎ ΠΈΠΌΡΠ½ΠΎΠΌΠ΅Π΄ΠΈΠΈΡΠ°Π½ ΠΏΡΠΎΡΠ΅Ρ, Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π°ΡΠ° ΡΠ° Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΈ, ΠΊΠΎΠΈΡΠΎ ΡΠ΅ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠΈΡΠ°Ρ Π² ΠΏΠ΅Π½Π΅ΡΡΠΈ ΠΊΠ»Π΅ΡΠΊΠΈ, Π’-ΠΊΠ»Π΅ΡΠΊΠΈ, Π°Π²ΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π°, Π°Π²ΡΠΎΠ°Π½ΡΠΈΠ³Π΅Π½ΠΈ, ΠΊΠΎΠΈΡΠΎ ΠΎΠ±ΠΈΡΠ°ΠΉΠ½ΠΎ ΡΠ° ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΈ Π½Π° ΡΡΠ΄ΠΎΠ²Π°ΡΠ° ΡΡΠ΅Π½Π°, Ρ ΠΎΠ»Π΅ΡΡΠ΅ΡΠΎΠ»ΠΎΠ²ΠΈ ΡΠ°ΡΡΠΈΡΠΈ ΠΈ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΈ, ΡΠ΅ΠΊΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΠΎΡ ΠΊΠ»Π΅ΡΠΊΠΈΡΠ΅, Π½Π°ΠΌΠΈΡΠ°ΡΠΈ ΡΠ΅ Π² Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΡΠΈΡΠ½ΠΈΡΠ΅ ΠΏΠ»Π°ΠΊΠΈ β IL-1, IL-2, IL-6, IL-8, IL-12, IL-10, TNF, INF-Ξ³ ΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅Π½ ΡΠ°ΡΡΠ΅ΠΆΠ΅Π½ ΡΠ°ΠΊΡΠΎΡ. ***** Summary. Antiphospholipid syndrome is an autoimmune disease characterized by circulating antibodies against different phospholipids and their co-protein factors. The base manifestation of antiphospholipid syndrome is thrombosis. This process involves the endothelial cells, monocytes, platelets, and complement. Endothelial cells and monocytes can be activated by antibodies against Ξ²2GPI.ο Many autoimmune diseases in rheumatologycal practice including. RA and SLE API are characterized by accelerated atherosclerosis and therefore an increased risk of cardiovascular disease and mortality. As an immune-mediated process macrophages are included in its pathogenesis, which are transformed into foam cells, T cells, autoantibodies, autoantigens, which are usually components of the vessel wall, cholesterol particles and cytokines secreted by the cells presented in atherosclerotic plaques such as IL-1, IL-2, IL-6, IL-8, IL-12, IL-10, TNF, INFΞ³ and platelet growth factor.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΡΠΎΡΠΈΠ°ΡΠΈΠ²Π½ΠΎ ΠΏΡΠΎΡΡΠ²Π°Π½Π΅ Π½Π° ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»Π΅Π½ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΡΠΌ Π² Π³Π΅Π½Π° Π·Π° ΡΡΠ°Π½ΡΡΠΎΡΠΌΠΈΡΠ°ΡΠΈΡ ΡΠ°ΡΡΠ΅ΠΆΠ΅Π½ ΡΠ°ΠΊΡΠΎΡ beta1ΠΏΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ΅Π½ Π»ΡΠΏΡΡ Π΅ΡΠΈΡΠ΅ΠΌΠ°ΡΠΎΠ΄Π΅Ρ Π² Π±ΡΠ»Π³Π°ΡΡΠΊΠ°ΡΠ° ΠΏΠΎΠΏΡΠ»Π°ΡΠΈΡ(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2012-04) ΠΠ°Π½ΠΎΠ»ΠΎΠ²Π°/Manolova, Π./I.; ΠΠ²Π°Π½ΠΎΠ²Π°/Ivanova, Π./M.; ΠΠ»Π΅ΠΊΡΠ°Π½Π΄ΡΠΎΠ²Π°/Aleksandrova, Π./E.; ΠΠΈΡΠ΅Π²Π°/Miteva, Π./L.; Π‘ΡΠΎΠΈΠ»ΠΎΠ²/Stoilov, Π ./R.; Π Π°ΡΠΊΠΎΠ²/Rashkov, Π ./R.; Π‘ΡΠ°Π½ΠΈΠ»ΠΎΠ²Π°/Stanilova, Π‘./S.; ΠΡΠ»ΡΠ±ΠΎΠ²Π°/Gulubova, Π./M.Π Π΅Π·ΡΠΌΠ΅. Π¦Π΅Π»ΡΠ° Π½Π° ΠΏΡΠΎΡΡΠ²Π°Π½Π΅ΡΠΎ Π±Π΅ΡΠ΅ Π΄Π° ΠΈΠ·ΡΠ»Π΅Π΄Π²Π°ΠΌΠ΅ ΡΠΎΠ»ΡΡΠ° Π½Π° ΠΏΡΠΎΠΌΠΎΡΠΎΡΠ΅Π½ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΡΠΌ - 509C/T Π² TGFΠ1 Π³Π΅Π½Π° Π·Π° ΠΏΡΠ΅Π΄ΡΠ°Π·ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ΡΠΎ ΠΊΡΠΌ ΡΠΈΡΡΠ΅ΠΌΠ΅Π½ Π»ΡΠΏΡΡ Π΅ΡΠΈΡΠ΅ΠΌΠ°ΡΠΎΠ΄Π΅Ρ (Π‘ΠΠ) ΠΈ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΠΈΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ½ΠΈ ΠΏΡΠΎΡΠ²ΠΈ Π½Π° Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅ΡΠΎ Π² Π±ΡΠ»Π³Π°ΡΡΠΊΠ°ΡΠ° ΠΏΠΎΠΏΡΠ»Π°ΡΠΈΡ. 149 Π»ΡΠΏΡΡΠ½ΠΎ Π±ΠΎΠ»Π½ΠΈ ΠΈ 134 Π·Π΄ΡΠ°Π²ΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈ Π±ΡΡ Π° Π³Π΅Π½ΠΎΡΠΈΠΏΠΈΠ·ΠΈΡΠ°Π½ΠΈ ΠΏΠΎ ΡΠΎΠ·ΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ΅Π½ ΠΌΠ°ΡΠΊΠ΅Ρ ΡΡΠ΅Π· Π°Π½Π°Π»ΠΈΠ· Π½Π° ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΡΠΌ ΠΏΠΎ Π΄ΡΠ»ΠΆΠΈΠ½Π°ΡΠ° Π½Π° ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠΎΠ½Π½ΠΈΡΠ΅ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΈ ΡΠ»Π΅Π΄ PCR ΡΠ΅Π°ΠΊΡΠΈΡ (RFLP-PCR). ΠΠ°ΠΊΠ°Ρ ΡΡΡΠ°Π½ΠΎΠ²Π΅Π½ΠΈΡΠ΅ Π°Π»Π΅Π»Π½ΠΈ ΡΠ΅ΡΡΠΎΡΠΈ ΠΏΠΎ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° ο509C/T ΡΡΠ΅Π΄ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΡΡ Π‘ΠΠ ΠΈ ΠΏΡΠΈ Π·Π΄ΡΠ°Π²ΠΈΡΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈ Π΄Π° Π±ΡΡ Π° ΡΡ ΠΎΠ΄Π½ΠΈ, ΠΏΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ Π±Π΅ΡΠ΅ Π½Π°Π±Π»ΡΠ΄Π°Π²Π°Π½Π° ΠΏΠΎ-Π²ΠΈΡΠΎΠΊΠ° ΡΠ΅ΡΡΠΎΡΠ° Π½Π° Ρ Π΅ΡΠ΅ΡΠΎΠ·ΠΈΠ³ΠΎΡΠ½ΠΈΡ Π³Π΅Π½ΠΎΡΠΈΠΏ (53%) Ρ Π±Π»ΠΈΠ·ΠΊΠ° Π΄ΠΎ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠ°ΡΠ° Π·Π½Π°ΡΠΈΠΌΠΎΡΡ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΡΡ Π·Π΄ΡΠ°Π²ΠΈΡΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈ (42%) Ρ OR = 1.52; 95% CI, 0.96 plus/minus 2.59, P = 0.059. ΠΡΠΈ Π±ΠΎΠ»Π½ΠΈΡΠ΅ Ρ Ρ Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΈ ΠΏΡΠΎΡΠ²ΠΈ Π±Π΅ΡΠ΅ ΡΡΡΠ°Π½ΠΎΠ²Π΅Π½Π° Π·Π½Π°ΡΠΈΠΌΠΎ ΠΏΠΎ-Π²ΠΈΡΠΎΠΊΠ° ΡΠ΅ΡΡΠΎΡΠ° Π½Π° Ρ Π΅ΡΠ΅ΡΠΎΠ·ΠΈΠ³ΠΎΡΠ½ΠΈΡ Π³Π΅Π½ΠΎΡΠΈΠΏ (60%) Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Ρ ΡΠ΅Π·ΠΈ Π±Π΅Π· Ρ Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΈ ΠΏΡΠΎΡΠ²ΠΈ (38%) Ρ OR = 2.41; 95%CI: 1.1 plus/minus 5.32; p = 0.016. ΠΠΎΡΠΈΡΠ΅Π»ΡΡΠ²ΠΎΡΠΎ Π½Π° Ρ Π΅ΡΠ΅ΡΠΎΠ·ΠΈΠ³ΠΎΡΠ½ΠΈΡ Π³Π΅Π½ΠΎΡΠΈΠΏ Π±Π΅ Π°ΡΠΎΡΠΈΠΈΡΠ°Π½ΠΎ ΠΈ Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ Π½Π° Π°Π½ΡΠΈ-Π΄Π²ΠΠΠ (OR = 2.108; 95%CI: 1.033 plus/minus 4.295; p = 0.04). Π Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅,ο509C/T ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΡΡ Π² TGF-beta-I Π³Π΅Π½Π° Π²Π»ΠΈΡΠ΅ Π²ΡΡΡ Ρ Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΎΡΠΎ ΠΏΡΠ΅Π΄ΡΠ°Π·ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ ΠΊΡΠΌ Π‘ΠΠ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ½ΠΈΡΠ΅ ΠΈΠ·ΡΠ²ΠΈ Π½Π° Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅ΡΠΎ Π² Π±ΡΠ»Π³Π°ΡΡΠΊΠ°ΡΠ° ΠΏΠΎΠΏΡΠ»Π°ΡΠΈΡ, ΠΊΠΎΠ΅ΡΠΎ Π³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Ρ ΠΊΠ°ΡΠΎ Π΅Π΄ΠΈΠ½ ΠΎΡ Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈΡΠ΅ ΡΠ°ΠΊΡΠΎΡΠΈ, Π΄ΠΎΠΏΡΠΈΠ½Π°ΡΡΡΠΈ Π·Π° ΠΊΠ»ΠΈΠ½ΠΈΡΠ½ΠΎΡΠΎ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·ΠΈΠ΅ Π½Π° Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅ΡΠΎ. ***** Summary. The aim of this study was to evaluate the association of ο509C/T promoter polymorphism of TGF-beta1 gene with systemic lupus erythematosus (SLE) and clinical features in Bulgarian population. A total of 149 patients with SLE and 134 healthy controls were genotyped for the ο509C/T polymorphism of TGF-beta1 by restriction fragment length polymorphism (RFLP)οο PCR assay. There were no significant differences in allele frequencies of ο509C>T polymorphism of TGF beta1 gene between the SLE patients and healthy controls. However, the frequency of heterozygous genotype among the SLE patients (53%) was higher compared to healthy controls (42%) with borderline significance and OR = 1.52; 95% CI, 0.96 plus/minus 2.59, P =0.059. In addition, heterozygous genotype was significantly higher in the SLE patients with haematological disorders (60%) compared to patients without these clinical features (38%) with OR = 2.41; 95%CI: 1.1 plus/minus 5.32; p = 0.016. The heterozygous genotype was also found to be slightly associated with anti-DNA positivity (OR = 2.0; 95%CI: 0.96 plus/minus 4.2; p = 0.045). In conclusion,our results suggest that ο509C > T polymorphism of TGF beta 1 may play a role in the susceptibility to SLE in the Bulgarian population. Also, TGF-beta1 polymorphism was related to specific clinical manifestations of the disease pointing TGF beta1 polymorphism as one of the genetic factors that explain the heterogeneity seen in/with SLE.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΡΠ»Π°ΠΌΠΈΠ» β Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΠΎ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΎ ΡΡΠ΅Π΄ΡΡΠ²ΠΎ Ρ Π΄ΠΎΠ±ΡΡ ΠΏΡΠΎΡΠΈΠ» Π½Π° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ ΠΈ Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2012-11) ΠΠ°ΡΠΈΠ½ΡΠ΅Π²Π°/Marincheva, Π‘./S.; Π Π°ΡΠΊΠΎΠ²/Rashkov, Π ./R.ΠΠ΄ΠΈΠ½ ΠΎΡ Π½Π°ΠΉ-Π²Π°ΠΆΠ½ΠΈΡΠ΅ ΡΠΈΠΌΠΏΡΠΎΠΌΠΈο οο Π½Π°ΠΉ-ΡΠ΅ΡΡΠΎ ΠΎΡΠ½ΠΎΠ²Π½ΠΈΡΡ, ΠΊΠΎΠΉΡΠΎ Π΄ΠΎΠ²Π΅ΠΆΠ΄Π° Π±ΠΎΠ»Π½ΠΈΡ Π² ΠΊΠ°Π±ΠΈΠ½Π΅ΡΠ° Π½Π° ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³Π°, Π΅ Π±ΠΎΠ»ΠΊΠ°ΡΠ°. ΠΡΠΈ Π΄ΡΡΠ³Π° ΡΠ°ΡΡ ΠΎΡ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ½ΠΎ Π±ΠΎΠ»Π½ΠΈΡΠ΅ ΡΠ΅ ΠΎΡΠΊΡΠΈΠ²Π°Ρ ΡΠΈΠΌΠΏΡΠΎΠΌΠΈ ΠΈΠ»ΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΈ, ΠΈΠ·ΡΠ°Π· Π½Π° Π»ΠΎΠΊΠ°Π»Π½ΠΎ ΠΈ/ΠΈΠ»ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎ Π²ΡΠ·ΠΏΠ°Π»Π΅Π½ΠΈΠ΅. Π Π² ΡΠΈΠΏΠΈΡΠ½ΠΈΡ ΡΠ»ΡΡΠ°ΠΉ ΡΠ° Π½Π°Π»ΠΈΡΠ΅ ΠΈ Π΄Π²Π΅ΡΠ΅ Π³ΡΡΠΏΠΈ ΠΎΠΏΠ»Π°ΠΊΠ²Π°Π½ΠΈΡ. Π’ΠΎΠ²Π° ΠΎΠ±ΡΡΠ½ΡΠ²Π° Π·Π°ΡΠΎ Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΠΈΡΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΡΠ·ΠΏΠ°Π»ΠΈΡΠ΅Π»Π½ΠΈ ΡΡΠ΅Π΄ΡΡΠ²Π° (ΠΠ‘ΠΠΠ‘), Π²ΠΊΠ». Π°ΡΠ΅ΠΊΠ»ΠΎΡΠ΅Π½Π°ΠΊ (Π°ΡΠ»Π°ΠΌΠΈΠ»), ΡΠ° Π΅Π΄Π½ΠΈ ΠΎΡ Π½Π°ΠΉ-ΡΠ΅ΡΡΠΎ ΠΈΠ·ΠΏΠΎΠ»Π·Π²Π°Π½ΠΈΡΠ΅ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½ΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈ Π² ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½Π°ΡΠ° ΠΏΡΠ°ΠΊΡΠΈΠΊΠ°. ΠΡ Π΄ΡΡΠ³Π° ΡΡΡΠ°Π½Π°, ΡΠΏΠΎΡΡΠ΅Π±Π°ΡΠ° ΠΈΠΌ ΡΠ΅ ΡΠ²ΡΡΠ·Π²Π° Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΡΠΎ Π½Π° ΡΠ΅Π΄ΠΈΡΠ° Π½Π΅ΠΆΠ΅Π»Π°Π½ΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½ΠΈ ΡΠ΅Π°ΠΊΡΠΈΠΈ (ΠΠΠ ). ΠΠ° ΠΏΡΡΠ²ΠΈΡΠ΅ Π΄Π²Π΅ ΠΌΠ΅ΡΡΠ° Π² ΠΊΠ»Π°Ρ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈΡΠ΅ ΡΠ΅ΡΠΈΠΎΠ·Π½ΠΈ ΠΠΠ ΡΠ° ΠΠ‘ΠΠΠ‘-Π°ΡΠΎΡΠΈΠΈΡΠ°Π½Π°ΡΠ° Π³Π°ΡΡΡΠΎΠΏΠ°ΡΠΈΡ ΠΈ Π²Π»ΠΈΡΠ½ΠΈΠ΅ΡΠΎ Π½Π° ΠΠ‘ΠΠΠ‘ Π²ΡΡΡ Ρ ΡΡΡΠ΄Π΅ΡΠ½ΠΎ-ΡΡΠ΄ΠΎΠ²Π°ΡΠ° ΡΠΈΡΡΠ΅ΠΌΠ°. Π’Π΅Π·ΠΈ Π΄Π²Π΅ Π³ΡΡΠΏΠΈ ΠΠΠ ΡΠ° ΠΎΡΠ½ΠΎΠ²Π½Π°ΡΠ° Π΄Π²ΠΈΠΆΠ΅ΡΠ° ΡΠΈΠ»Π° ΠΏΡΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ²Π°Π½Π΅ΡΠΎ Π½Π° Π½ΠΎΠ²ΠΈΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»ΠΈ ΠΠ‘ΠΠΠ‘. Π‘ΡΠ΅Π΄ ΡΡΡ Π°ΡΠ΅ΠΊΠ»ΠΎΡΠ΅Π½Π°ΠΊ ΡΠ΅ ΠΎΡΠΊΡΠΎΡΠ²Π° Ρ Π΄ΠΎΠ±ΡΠΈΡ ΡΠΈ ΠΏΡΠΎΡΠΈΠ» Π½Π° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ ΠΈ Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ. Π ΠΎΠ±Π·ΠΎΡΠ° ΡΠ° ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π΅Π½ΠΈ ΠΊΠ»Π°Ρ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈΡΠ΅ ΠΠΠ Π½Π° ΠΠ‘ΠΠΠ‘, ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΊΠΈΠ½Π΅ΡΠΈΠΊΠ°ΡΠ° ΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ°ΡΠ°, ΠΊΠ°ΠΊΡΠΎ ΠΈ ΡΠ΅Π·ΡΠ»ΡΠ°ΡΠΈ ΠΎΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ½ΠΈ ΠΈΠ·ΠΏΠΈΡΠ²Π°Π½ΠΈΡ, ΠΎΡΠ΅Π½ΡΠ²Π°ΡΠΈ ΠΏΡΠΎΡΠΈΠ»Π° Π½Π° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ ΠΈ Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ Π½Π° Π°ΡΠ΅ΠΊΠ»ΠΎΡΠ΅Π½Π°ΠΊ. ****** Summary. The most important and basic symptom that brings the patient to the rheumatologist is pain. In other cases, the rheumatic diseased patient manifests symptoms or syndromes, reflecting local and/or systemic inflammation, while typically, both types of complaints are presented. This explains why nonsteroidal anti-inflammatory drugs (NSAIDs), including Aceclofenac (Aflamil), are among the most frequently used drugs in rheumatologic practice. On the other hand, the use of NSAID is associated with the development of a number of drug-related adverse events (AE). The most significant class-specific serious AEs are NSAID-associated gastric damages and the impact of NSAID on the cardiovascular system. These two groups AEs are the main driving force that pushes the development of new agents NSAID. Aceclofenac stands out of the NSAID with a good safety profile and efficacy. Data on the class-specific AE of NSAID, pharmacokinetics and pharmacodynamics, and results from clinical trials evaluating the safety and efficacy profile of Aceclofenac are presented in this article.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΡΠ·ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²ΠΎ Π½Π° Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΠ΅ΡΠΎ ΠΈ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΠΎ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π½Π° ΠΆΠ΅Π½ΠΈΡΠ΅ Π² ΠΡΠ»Π³Π°ΡΠΈΡ Π·Π° ΠΏΠ΅ΡΠΈΠΎΠ΄Π° 1977/ 1996 Π³. ΠΠ΅Π΄ΠΈΠΊΠΎΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π°Π½Π°Π»ΠΈΠ· // Reproduction of the population and reproductive attitude of Bulgarian women for the period 1977-1996. Medicostatistical analysis(Π¦ΠΠ - ΠΠ£ Π‘ΠΎΡΠΈΡ, 2000) ΠΠ°ΡΡΠΎΠ²Π°, ΠΠΈΠ΄ΠΈΡ // Katrova, LydiaΠ Π΅Π·ΡΠΌΠ΅: ΠΠ° Π±Π°Π·Π°ΡΠ° Π½Π° ΠΎΡΠΈΡΠΈΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΠΊΠΎΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠ° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎΡ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° 1975-1996 Π³ΠΎΠ΄ΠΈΠ½Π° Π΅ Π½Π°ΠΏΡΠ°Π²Π΅Π½ Π°Π½Π°Π»ΠΈΠ· Π½Π° ΡΠ΅Π°Π»Π½ΠΈΡΠ΅ ΠΈ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»Π½ΠΈ Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π½ΠΈΡΠ΅ ΠΏΡΠ΅Π΄ΠΏΠΎΡΡΠ°Π²ΠΊΠΈ ΠΈ ΡΠ°ΠΊΡΠΎΡΠΈ Π·Π° Π²ΡΠ·ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²ΠΎΡΠΎ Π½Π° Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΠ΅ΡΠΎ Π² ΠΡΠ»Π³Π°ΡΠΈΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π΅Π½ΠΈΡΠ΅ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠΈ ΡΠ° ΡΡΠ°Π²Π½Π΅Π½ΠΈ Ρ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠΈΡΠ΅ Π² ΡΡΡΠ°Π½ΠΈΡΠ΅ b ΠΏΡΠ΅Ρ ΠΎΠ΄ ΠΈ Π΅Π²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΈΡΠ΅ ΡΡΡΠ°Π½ΠΈ. ΠΡΠ΅ΡΡΠ°Π½ΠΈ ΡΠ° ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈ Π·Π° Π΄Π΅ΠΌΠΎΠ³ΡΠ°ΡΡΠΊΠΎΡΠΎ ΡΡΡΡΠΎΡΠ½ΠΈΠ΅ Π½Π° ΡΡΡΠ°Π½Π°ΡΠ° Π² ΠΊΠΎΠ½ΡΠ΅ΠΊΡΡΠ° Π½Π° ΠΈΠ·Π³ΡΠ°ΠΆΠ΄Π°Π½Π΅ Π½Π° Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½Π° ΠΏΠΎΠ»ΠΈΡΠΈΠΊΠ° Π½Π° Π·Π΄ΡΠ°Π²Π½ΠΎ ΠΎΡΠΈΠ³ΡΡΡΠ²Π°Π½Π΅. // Summary: On the base of the official medicostatistical information for the period 1975-1996 a secondary analysis was made of real and potential influences of basic prerequisites and factors for reproduction of the population in Bulgaria. Established trends are compared to those observed in the countries of transition as well as in European countries. The prognostic is made in the context of building adequate policy for health assurance.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΠ΅Π½Π΅ΡΠΈΠΊΠ° Π² ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΡΠ°(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2012-04) Π¨ΡΠΌΠ½Π°Π»ΠΈΠ΅Π²Π°/Shumnalieva, Π ./R.; ΠΠΎΠ»Π°ΡΠΎΠ²/Kolarov, ΠΠ»./Zl.Π Π΅Π·ΡΠΌΠ΅. ΠΠ΅Π½Π΅ΡΠΈΡΠ½ΠΈΡΠ΅ ΡΠ°ΠΊΡΠΎΡΠΈ ΠΈ ΡΠ°ΠΊΡΠΎΡΠΈΡΠ΅ Π½Π° ΠΎΠΊΠΎΠ»Π½Π°ΡΠ° ΡΡΠ΅Π΄Π° ΠΈΠΌΠ°Ρ ΡΡΡΠ΅ΡΡΠ²Π΅Π½ΠΎ ΡΡΠ°ΡΡΠΈΠ΅ Π² Π΅ΡΠΈΠΎΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π°ΡΠ° Π½Π° Π°Π²ΡΠΎΠΈΠΌΡΠ½Π½ΠΈΡΠ΅ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ. ΠΠ΅Π½ΠΈΡΠ΅ Π²Π»ΠΈΡΡΡ Π½Π° Π΅Π½Π·ΠΈΠΌΠ½Π°ΡΠ° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡ ΠΈ ΡΠΈΠ½ΡΠ΅Π·Π° Π½Π° ΡΠΈΡΠΎΠΊΠΈΠ½ΠΈ, ΠΊΠΎΠ΄ΠΈΡΠ°Ρ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ½ΠΈ Π°ΠΊΡΠΈΠ²Π°ΡΠΎΡΠΈ ΠΈ Ρ.Π½. ΠΠΎΡΠΈΡΠ΅Π»ΡΡΠ²ΠΎΡΠΎ Π½Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈ Π³Π΅Π½ΠΈ Π½Π΅ ΡΠ°ΠΌΠΎ ΠΏΡΠ΅Π΄ΠΎΠΏΡΠ΅Π΄Π΅Π»Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΡΠΎ Π½Π° Π΄Π°Π΄Π΅Π½Π° Π±ΠΎΠ»Π΅ΡΡ, Π½Π΅ΠΉΠ½Π°ΡΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠ½Π° ΠΈΠ·ΡΠ²Π° ΠΈ Π½Π°ΡΠΈΠ½Π° Π½Π° ΠΏΡΠΎΡΠΈΡΠ°Π½Π΅, Π½ΠΎ Π²Π»ΠΈΡΠ΅ ΠΈ Π²ΡΡΡ Ρ Π΅ΡΠ΅ΠΊΡΠ° ΠΎΡ ΠΏΡΠΎΠ²Π΅ΠΆΠ΄Π°Π½ΠΎΡΠΎ Π»Π΅ΡΠ΅Π½ΠΈΠ΅. ΠΠ±Π·ΠΎΡΡΡ ΠΈΠΌΠ° Π·Π° ΡΠ΅Π» Π΄Π° ΡΠ°Π·ΡΡΠ½ΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΠΈΡΠ΅ Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈ ΠΏΠΎΠ½ΡΡΠΈΡ, ΠΊΠΎΠΈΡΠΎ ΠΈΠΌΠ°Ρ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΊΡΠΌ ΠΏΡΠ΅Π΄ΠΈΡΠΏΠΎΠ·ΠΈΡΠΈΡΡΠ° ΠΊΡΠΌ ΠΎΡΠ½ΠΎΠ²Π½ΠΈΡΠ΅ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ½ΠΈ Π±ΠΎΠ»Π΅ΡΡΠΈ, ΠΊΠ°ΡΠΎ Π·Π°ΠΊΠΎΠ½ΠΈΡΠ΅ Π½Π° ΠΠ΅Π½Π΄Π΅Π», ΠΏΠ΅Π½Π΅ΡΡΠ°Π½ΡΠ½ΠΎΡΡ ΠΈ Π΅ΠΊΡΠΏΡΠ΅ΡΠΈΠ²Π½Π° Π²Π°ΡΠΈΠ°Π±ΠΈΠ»- Π½ΠΎΡΡ, ΡΠ΅Π½ΠΎΠΊΠΎΠΏΠΈΡ ΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈ Π²Π°ΡΠΈΠ°Π½ΡΠΈ. ***** Summary. Genetic and environmental factors contribute significantly to etiopathogenesis of autoimmune rheumatic diseases. Genes affect enzyme activity and cytokine ynthesis, encode receptor activators, etc. The presence of certain genes not only predetermines the occurrence of a disease, its clinical manifestation and mode of progression, but also influences the effect of therapy. This review clarifies basic genetic concepts, related with predisposition to main rheumatic diseases, such as Mendelβs laws, penetrance and variable expression, phenocopies and genetic variants.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΠ»ΠΎΠ±Π°Π»Π½ΠΈ Π²Π»ΠΈΡΠ½ΠΈΡ Π²ΡΡΡ Ρ Π·Π΄ΡΠ°Π²Π΅ΠΎΠΏΠ°Π·Π²Π°Π½Π΅ΡΠΎ ΠΈ Π³Π»ΠΎΠ±Π°Π»Π½ΠΈ ΠΎΡΠ³ΠΎΠ²ΠΎΡΠΈ Π½Π° Π·Π΄ΡΠ°Π²Π½ΠΈΡΠ΅ ΠΏΡΠΎΡΠ΅ΡΠΈΠΈ. ΠΡΠΎΠ±Π΅Π½ΠΎΡΡΠΈ Π½Π° ΠΏΡΠΎΡΠ΅ΡΠΈΠΎΠ½Π°Π»ΠΈΠ·Π°ΡΠΈΡΡΠ° Π² ΠΎΠ±ΡΠ΅ΡΡΠ²Π° Π½Π° ΠΏΡΠ΅Ρ ΠΎΠ΄.ΠΠ°ΡΡΠΎΠ²Π°, ΠΠΈΠ΄ΠΈΡ // Katrova, LydiaΠ Π°Π·Π²ΠΈΡΠΈΠ΅ΡΠΎ Π½Π° Π·Π΄ΡΠ°Π²Π΅ΠΎΠΏΠ°Π·Π²Π°Π½Π΅ΡΠΎ Π² ΠΌΠΎΠ΄Π΅ΡΠ½ΠΈΡΠ΅ ΠΎΠ±ΡΠ΅ΡΡΠ²Π° ΡΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Ρ ΠΎΡ Π½ΡΠΊΠΎΠ»ΠΊΠΎ ΠΎΡΠ½ΠΎΠ²Π½ΠΈ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠΈ: Π΄Π΅ΠΌΠΎΠ³ΡΠ°ΡΡΠΊΠΈ ΠΏΡΠ΅Ρ ΠΎΠ΄,Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΈΡΠ°Ρ ΡΠ΅ Ρ Π½Π°ΠΌΠ°Π»ΡΠ²Π°Π½Π΅ Π½Π° ΡΠ°ΠΆΠ΄Π°Π΅ΠΌΠΎΡΡΡΠ°, Π½Π°ΠΌΠ°Π»ΡΠ²Π°Π½Π΅ Π½Π° Π΄Π΅ΡΡΠΊΠ°ΡΠ° ΡΠΌΡΡΡΠ½ΠΎΡΡ ΠΈ ΡΠ²Π΅Π»ΠΈΡΠ°Π²Π°Π½Π΅ Π½Π° ΠΏΡΠΎΠ΄ΡΠ»ΠΆΠΈΡΠ΅Π»Π½ΠΎΡΡΡΠ° Π½Π° ΠΆΠΈΠ²ΠΎΡΠ°, ΠΊΠ°ΠΊΡΠΎ ΠΈ ΡΡΠ°ΠΉΠ½Π° ΠΏΡΠΎΠΌΡΠ½Π° Π² ΡΡΡΡΠΊΡΡΡΠ°ΡΠ° Π½Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡΠ°, ΠΈΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈ ΠΏΡΠ΅Ρ ΠΎΠ΄, Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΈΡΠ°Ρ ΡΠ΅ ΠΈΠ½Π΄ΡΡΡΡΠΈΠ°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΈ ΡΡΠ±Π°Π½ΠΈΠ·Π°ΡΠΈΡ, ΠΏΡΠ΅Ρ ΠΎΠ΄ Π² ΡΠΎΡΠΈΠ°Π»Π½ΠΎΡΠΎ ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠ΅. ΠΡΠΎΡΠ΅ΡΠΈΡΠ΅ Π½Π° Π³Π»ΠΎΠ±Π°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΏΠΎΡΡΠ°Π²ΡΡ ΠΏΡΠ΅Π΄ ΡΠ΅ΡΠΈΠΎΠ·Π½ΠΈ ΠΏΡΠ΅Π΄ΠΈΠ·Π²ΠΈΠΊΠ°ΡΠ΅Π»ΡΡΠ²Π° Π·Π΄ΡΠ°Π²Π΅ΠΎΠΏΠ°Π·Π²Π°Π½Π΅ΡΠΎ, ΠΊΠ°ΡΠΎ ΡΠ°ΡΡ ΠΎΡ ΡΠΎΡΠΈΠ°Π»Π½Π°ΡΠ° ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ, ΠΎΡΠΎΠ±Π΅Π½ΠΎ Π·Π° ΡΡΡΠ°Π½ΠΈΡΠ΅ Π² ΠΏΡΠ΅Ρ ΠΎΠ΄ ΠΎΡ ΠΠ·ΡΠΎΡΠ½Π° ΠΈ Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΠ²ΡΠΎΠΏΠ°. ΠΠ°ΡΠΎ ΠΎΡΠ½ΠΎΠ²Π΅Π½ ΠΏΡΠΎΠ±Π»Π΅ΠΌ ΡΠ΅ ΠΎΡΠ΅ΡΡΠ°Π²Π° Π΄Π΅ΡΠΈΠ½ΠΈΡΠ°Π½Π΅ΡΠΎ Π½Π° Π·Π΄ΡΠ°Π²Π½ΠΈΡΠ΅ ΡΠΈΡΠΊΠΎΠ²Π΅ Π² ΠΏΠΎ-ΡΠΈΡΠΎΠΊ ΡΠΎΡΠΈΠΎΠΈΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈ ΠΊΠΎΠ½ΡΠ΅ΠΊΡΡ ΠΈ Π±ΠΎΡΠ±Π°ΡΠ° Ρ Π΄ΡΠ°ΡΡΠΈΡΠ½ΠΈΡΠ΅ Π½Π΅ΡΠ°Π²Π΅Π½ΡΡΠ²Π° ΡΠΏΡΡΠΌΠΎ Π΄ΠΎΡΡΡΠΏ Π΄ΠΎ Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½ΠΈ Π·Π΄ΡΠ°Π²Π½ΠΈ Π³ΡΠΈΠΆΠΈ
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΠΏΠΈΠ³Π΅Π½Π΅ΡΠΈΠΊΠ° Π² ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΡΠ°.(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ / Central Medical Library, MU β Sofia, 2011-12) Π¨ΡΠΌΠ½Π°Π»ΠΈΠ΅Π²Π°/Shumnalieva, Π ./R.; ΠΠΎΠ»Π°ΡΠΎΠ²/Kolarov, ΠΠ»./Zl.Π Π΅Π·ΡΠΌΠ΅. ΠΡΠ΅Π· ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΎΡΠΎ Π΄Π΅ΡΠ΅ΡΠΈΠ»Π΅ΡΠΈΠ΅ ΡΠ΅ ΠΏΠΎΠ»Π°Π³Π°Ρ Π³ΠΎΠ»Π΅ΠΌΠΈ ΡΡΠΈΠ»ΠΈΡ ΠΏΡΠΈ ΠΈΠ·ΡΡΠ°Π²Π°Π½Π΅ Π½Π° ΠΌΠΎΠ»Π΅ΠΊΡΠ»Π½ΠΎ Π½ΠΈΠ²ΠΎ Π½Π° Π΅ΡΠΈΠΎΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈΡΠ΅ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΈ Π½Π° ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ½ΠΈΡΠ΅ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ. ΠΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π° ΡΠ΅, ΡΠ΅ ΠΏΠΎΡΠ²Π°ΡΠ° ΠΈΠΌ Π΅ ΡΠ΅Π·ΡΠ»ΡΠ°Ρ Π½Π° Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΡΠΎ ΠΌΠ΅ΠΆΠ΄Ρ Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈ, Ρ ΠΎΡΠΌΠΎΠ½Π°Π»Π½ΠΈ, ΠΈΠΌΡΠ½Π½ΠΈ ΠΈ ΡΠ°ΠΊΡΠΎΡΠΈ Π½Π° ΠΎΠΊΠΎΠ»Π½Π°ΡΠ° ΡΡΠ΅Π΄Π°. ΠΡΡΠ·ΠΊΠ°ΡΠ° ΠΌΠ΅ΠΆΠ΄Ρ Π΅ΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΈΡΠ΅ ΡΠ°ΠΊΡΠΎΡΠΈ ΡΠ΅ ΠΎΡΡΡΠ΅ΡΡΠ²ΡΠ²Π° ΡΡΠ΅Π· ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΈ Π½Π° Π΅ΠΏΠΈΠ³Π΅Π½Π΅ΡΠΈΡΠ½Π° ΡΠ΅Π³ΡΠ»Π°ΡΠΈΡ, ΠΊΠΎΠΈΡΠΎ ΠΏΠΎΠ²Π»ΠΈΡΠ²Π°Ρ Π³Π΅Π½Π½Π°ΡΠ° Π΅ΠΊΡΠΏΡΠ΅ΡΠΈΡ. ΠΡ ΡΠ²ΠΎΡ ΡΡΡΠ°Π½Π° Π΅ΠΏΠΈΠ³Π΅Π½Π΅ΡΠΈΡΠ½Π°ΡΠ° ΡΠ΅Π³ΡΠ»Π°ΡΠΈΡ ΡΡΡΠΎ Π΅ ΠΎΠ±Π΅ΠΊΡ Π½Π° Π²ΡΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π½Π° ΡΠ°ΠΊΡΠΎΡΠΈΡΠ΅ Π½Π° ΠΎΠΊΠΎΠ»Π½Π°ΡΠ° ΡΡΠ΅Π΄Π°. ΠΠ·ΡΡΠ½ΡΠ²Π°Π½Π΅ΡΠΎ Π½Π° ΡΠ΅Π·ΠΈ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΈ Π΅ ΠΎΠ±Π΅ΠΊΡ Π½Π° Π½Π°ΡΡΠΎΡΡΠΈ ΠΈ Π±ΡΠ΄Π΅ΡΠΈ ΠΏΡΠΎΡΡΠ²Π°Π½ΠΈΡ, ΡΠ΅Π·ΡΠ»ΡΠ°ΡΠΈΡΠ΅ ΠΎΡ ΠΊΠΎΠΈΡΠΎ Π²Π΅ΡΠΎΡΡΠ½ΠΎ ΡΠ΅ ΠΏΡΠ΅Π΄ΠΎΡΡΠ°Π²ΡΡ ΠΈ Π½ΠΎΠ²ΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½ΠΈ Π²ΡΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΡΠΈ ΡΠ΅Π·ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ. ***** Summary. Over the last decade great endeavors are being made to study the etiopathogenetic mechanisms of rheumatic diseases at molecular level. It is believed that their appearance is a result from the interaction between genetic, hormonal, immune and environmental factors. The relationship between the etiological factors is made through mechanisms of epigenetic regulation that affect gene expression. In turn, epigenetic regulation is also a subject of influence of environmental factors. Clarifying these mechanisms is the subject of current and future studies, the results of which will likely provide new therapeutic options for these diseases.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° Π½Π° ΠΊΠΎΠΆΠ½ΠΈΡΠ΅ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ Π² Π΄Π΅ΡΡΠΊΠ° Π²ΡΠ·ΡΠ°ΡΡ.(Π€Π°ΠΊΡΠ»ΡΠ΅Ρ ΠΏΠΎ ΠΠ±ΡΠ΅ΡΡΠ²Π΅Π½ΠΎ ΠΠ΄ΡΠ°Π²Π΅, 2011) ΠΡΠ±ΠΎΠΌΠΈΡΠΎΠ²Π°/Lyubomirova, ΠΠ°ΡΠΎΠ»ΠΈΠ½Π°/Karolina; Π¦Π°ΡΠ΅Π²Π°/Tzacheva, ΠΠ΅Π²Π΅Π½Π°/Nevena; ΠΠ΅ΡΡΠΎΠ²/Petrov, Π./I.; ΠΠ΅Π½ΡΠ΅Π²Π°/Dencheva, Π ./R.; ΠΠ²ΡΡΠ°ΡΠΈΠ΅Π²Π°/Evstatieva, Π‘ΠΎΡΠΈΡ/Sofia; ΠΠ»Π°Π΄Π΅Π½ΠΎΠ²Π°/Mladenova, Π‘./S.; ΠΠΎΠΏΠΎΠ²Π°/Popova, ΠΡ./Kr.Π Π΅Π·ΡΠΌΠ΅: ΠΠ°ΠΏΡΠ°Π²Π΅Π½ Π΅ ΠΎΠ±Π·ΠΎΡ Π½Π° ΡΠ°Π·ΠΏΡΠΎΡΡΡΠ°Π½ΠΈΠ΅ΡΠΎ Π½Π° Π½ΡΠΊΠΎΠΈ ΠΊΠΎΠΆΠ½ΠΈ ΠΈ Π²Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ Π² Π΄Π΅ΡΡΠΊΠ° Π²ΡΠ·ΡΠ°ΡΡ. ΠΠΎΡΠΎΡΠ΅Π½Π° Π΅ Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎΡΡΡΠ° ΠΎΡ ΠΏΡΠΎΠ²Π΅ΠΆΠ΄Π°Π½Π΅ Π½Π° ΠΏΠΎΠ΄ΡΠΎΠ±Π½ΠΎ ΠΏΡΠΎΡΡΠ²Π°Π½Π΅ Π½Π° ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° Π² ΠΡΠ»Π³Π°ΡΠΈΡ. Π§Π°ΡΡ ΠΎΡ ΠΊΠΎΠΆΠ½ΠΈΡΠ΅ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ ΡΠ΅ ΠΏΡΠΎΡΠ²ΡΠ²Π°Ρ Π² Π΄Π΅ΡΡΠΊΠ° Π²ΡΠ·ΡΠ°ΡΡ ΠΈ Π±Π΅Π· ΠΏΠΎΠ΄Ρ ΠΎΠ΄ΡΡΠΎ ΠΈ Π½Π°Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ³ΡΠ΅ΡΠΈΡΠ°Ρ ΠΈ ΡΠ΅ Π·Π°Π΄ΡΠ»Π±ΠΎΡΠ°Π²Π°Ρ Π² Π·ΡΡΠ»Π° Π²ΡΠ·ΡΠ°ΡΡ. Π’ΠΎΠ²Π° Π½Π°Π»Π°Π³Π° ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ Π½Π° Π΄Π΅ΡΠ°ΡΠ° Π² ΠΏΡΠ΅Π΄ΡΡΠΈΠ»ΠΈΡΠ½Π° ΠΈ ΡΡΠΈΠ»ΠΈΡΠ½Π° Π²ΡΠ·ΡΠ°ΡΡ Ρ ΡΠ΅Π» ΡΠ°Π½Π½Π° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π° Π²ΡΠ·Π½ΠΈΠΊΠ½Π°Π»ΠΈ ΠΊΠΎΠΆΠ½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ. ΠΠΎΠ±ΡΠ°ΡΠ° ΠΈΠ½ΡΠΎΡΠΌΠΈΡΠ°Π½ΠΎΡΡ Π½Π° ΡΡΠ΅Π½ΠΈΡΠΈΡΠ΅ ΠΈ ΡΠ΅Ρ Π½ΠΈΡΠ΅ ΡΠΎΠ΄ΠΈΡΠ΅Π»ΠΈ ΡΠ΅ Π΄ΠΎΠΏΡΠΈΠ½Π΅ΡΠ΅ Π·Π° ΡΠ°Π·ΠΏΠΎΠ·Π½Π°Π²Π°Π½Π΅ Π½Π° ΡΠ°Π½Π½ΠΈΡΠ΅ ΡΠΈΠΌΠΏΡΠΎΠΌΠΈ Π½Π° Π½ΡΠΊΠΎΠΈ ΠΊΠΎΠΆΠ½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ ΠΈ Π΄ΠΎ ΡΡΡ Π½Π°ΡΠ° Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½Π° ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ°. ********************************************* Abstract A review of the prevalence of some skin and venereal diseases in childhood is presented. The necessity of a profound study of the problem in Bulgaria is underlined. Some of the skin diseases appear in childhood. Without an adequate treatment in time the symptoms can progress and go deeper in adolescence. That is why a screening of the children is needed which will enhance the early diagnostics and treatment of newly developed skin diseases. The information of the children and their parents will contribute to the recognition of the first symptoms of some skin diseases and to their adequate prophylactics.
- ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ Π½Π° ΠΈΠ½ΠΆΠ΅ΠΊΡΠΈΠΎΠ½Π½ΠΈΡ ΠΊΠΎΠ»Π°Π³Π΅Π½ GUNA MD ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π° ΠΎΡΡΠ΅ΠΎΠ°ΡΡΡΠΎΠ·Π° Π½Π° ΠΊΠΎΠ»ΡΠ½Π½Π° ΡΡΠ°Π²Π° // Efficacy and safety of GUNA MD injection collagen in the treatment of gonarthrosis(Π¦Π΅Π½ΡΡΠ°Π»Π½Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠ°, ΠΠ£ Π‘ΠΎΡΠΈΡ // Central Medical Library, MU β Sofia, 2012-11) Π Π΅ΡΠΊΠΎΠ²Π°, Π. // Reshkova, V.; Π Π°ΡΠΊΠΎΠ², Π . // Rashkov, R.; ΠΠ΅ΡΡΠΎΡΠΎΠ²Π°, Π . // Nestorova, R.; ΠΠ°Π»ΠΈΠ½ΠΎΠ²Π°, Π. // Kalinova, D.Π£ΡΠΏΠ΅ΡΠ½ΠΈΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ Π·Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π° ΡΠΊΠ΅Π»Π΅ΡΠ½ΠΎ-ΠΌΡΡΠΊΡΠ»Π½ΠΎ-Π½Π΅Π²ΡΠ°Π»Π³ΠΈΡΠ½Π°ΡΠ° ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ ΡΡΡΠ±Π²Π° Π΄Π° ΠΏΡΠΈΡΠ΅ΠΆΠ°Π²Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° β Π΄Π° Π΄Π΅ΠΉΡΡΠ²Π° ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ½ΠΎ, Π»ΠΎΠΊΠ°Π»Π½ΠΎ, Π΄Π° ΠΏΡΠΈΡΠ΅ΠΆΠ°Π²Π° ΡΡΠΎΠΏΠΈΠ·ΡΠΌ ΠΊΡΠΌ ΡΠ²ΡΠ΅Π΄Π΅Π½ΠΈΡΠ΅ ΡΡΡΡΠΊΡΡΡΠΈ, Π΄Π° Π΄Π΅ΠΉΡΡΠ²Π° Π½Π° ΠΎΠΊΠΎΠ»ΠΎΡΡΠ°Π²Π½ΠΈΡΠ΅ ΡΡΡΡΠΊΡΡΡΠΈ ΠΈ Π²ΡΡΡΠ΅ΡΡΠ°Π²Π½ΠΎ. Π‘ΡΠΈΡΠ° ΡΠ΅, ΡΠ΅ ΠΊΠΎΠ»Π°Π³Π΅Π½ΡΡ Π² GUNA-MD ΠΏΡΠΈΡΠ΅ΠΆΠ°Π²Π° ΡΠ΅Π·ΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π°. ΠΠ° ΠΏΠ΅ΡΠΈΠΎΠ΄Π° Π°ΠΏΡΠΈΠ» 2011βΠ°Π²Π³ΡΡΡ 2011 Π³. ΡΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ½ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π² ΠΠ»ΠΈΠ½ΠΈΠΊΠ°ΡΠ° ΠΏΠΎ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈ ΠΠ¦ βΠ‘Π². ΠΡΠΈΠ½Π°β Ρ Π²ΡΡΡΠ΅ΡΡΠ°Π²Π½ΠΎ ΠΏΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ Π½Π° ΠΊΠΎΠ»Π°Π³Π΅Π½. ΠΡΠΈ 30 Π±ΠΎΠ»Π½ΠΈ Ρ Π³ΠΎΠ½Π°ΡΡΡΠΎΠ·Π° ΠΠ RΓΆ ΡΡΠ°Π΄ΠΈΠΉ Π±Π΅Π· ΠΎΡΠΎΠΊ Π΅ ΠΈΠ·Π²ΡΡΡΠ΅Π½ 8-ΡΠ΅Π΄ΠΌΠΈΡΠ΅Π½ ΠΊΡΡΡ Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Ρ Π²ΡΡΡΠ΅ΡΡΠ°Π²Π½ΠΎ ΠΏΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ Π½Π° GUNA MD KNEE + GUNA MD MUSCLE. ΠΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΡΠ° ΠΏΡΠΎΡΠ»Π΅Π΄Π΅Π½ΠΈ ΠΏΡΠ΅Π΄ΠΈ ΠΈ Π² ΠΊΡΠ°Ρ Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ ΠΈ 30 Π΄Π½ΠΈ ΡΠ»Π΅Π΄ ΠΏΡΠΈΠΊΠ»ΡΡΠ²Π°Π½Π΅ Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ. ΠΠ·ΠΏΠΎΠ»Π·Π²Π°Π½ΠΈ ΡΠ° Π²ΡΠΏΡΠΎΡΠ½ΠΈΡΠΈ Π·Π° ΠΎΡΠ΅Π½ΠΊΠ° Π½Π° ΠΏΡΠΎΠΌΡΠ½Π°ΡΠ° Π½Π° Π±ΠΎΠ»ΠΊΠ°ΡΠ° ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»Π½ΠΈΡ ΠΈΠ½Π΄Π΅ΠΊΡ Π½Π° Lequesne, ΠΏΠΎΠΏΡΠ»Π²Π°Π½ΠΈ ΠΎΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΠΏΡΠ΅Π΄ΠΈ ΠΈ Π² ΠΊΡΠ°Ρ Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ. Π Π΅Π·ΡΠ»ΡΠ°ΡΠΈΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π²Π°Ρ, ΡΠ΅ Π²ΡΡΡΠ΅ΡΡΠ°Π²Π½ΠΎΡΠΎ ΠΏΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ Π½Π° GUNA MD ΠΏΡΠΈ Π³ΠΎΠ½Π°ΡΡΡΠΎΠ·Π° ΠΏΠΎΠ²Π»ΠΈΡΠ²Π° ΡΠΈΠ³Π½ΠΈΡΠΈΠΊΠ°Π½ΡΠ½ΠΎ Π±ΠΎΠ»ΠΊΠ°ΡΠ° Π² ΠΏΠΎΠΊΠΎΠΉ, ΠΏΡΠΈ Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»Π½Π°ΡΠ° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. ΠΠ΅ ΡΠ΅ Π½Π°Π±Π»ΡΠ΄Π°Π²Π°Ρ ΡΡΡΠ°Π½ΠΈΡΠ½ΠΈ ΡΠ΅Π°ΠΊΡΠΈΠΈ ΠΏΡΠΈ ΠΏΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ΡΠΎ Π½Π° GUNA. // Summary. Collagen is the most abundant protein (structural protein-tissue; molecular weight 300 KDa) in the mammalian organism, accounting for about 5-6% of the human adultβs body weight. A new substantial and refined approach to painful dysfunctional pathologies of the musculoskeletal system and related motor dysfunctions is proposed now by Guna Medical Devices for use in clinical practice and specialized facilities. Guna Medical Devices contain collagen and ancillary substances of natural origin. Thirty patients with gonarthrosis of II X-ray stage were monitored for a 3-month period and re-examined after 8-week administration of GUNA-MD KNEE + GUNA MD MUSCLE injections. The patients were evaluated by using a questionnaire of pain and functional index of Lequesne before and after the treatment. Intra-articular application of GUNA-MD in gonarthrosis has been shown to improve significantly pain at rest and while moving, as well as the functional activity of the patients.
